[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2204
1. Bruna Esteban M, Montalvá Orón E, López Delgado A, Galindo Jara P, Vázquez Prado A, Fabra Ramis R: [Gastric adenocarcinoma in Zinsser-Cole-Engman syndrome]. Cir Esp; 2006 Sep;80(3):176-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in Zinsser-Cole-Engman syndrome].
  • [Transliterated title] Adenocarcinoma gástrico en el síndrome de Zinsser-Cole-Engman.
  • We report the case of a 37-year-old man with this syndrome who was diagnosed with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Dyskeratosis Congenita / complications. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956556.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res; 2006 Jul-Aug;26(4B):2909-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.
  • BACKGROUND: The genetic events involved in gastric cancer, the third most frequent cancer in the world with a high incidence in Pard State, Brazil, remain largely unknown.
  • MATERIALS AND METHODS: Twenty-one primary gastric adenocarcinomas were investigated by comparative genomic hybridization (CGH) and the relationships between genomic abnormalities and histopathological features were evaluated.
  • CONCLUSION: C-MYC locus amplification may be predictor of aggressiveness in intestinal-type gastric cancer, playing an important role in its development and progression.
  • Gastric adenocarcinomas of differing histopathological features were associated with distinct genetic alterations, supporting the hypothesis that they evolve through distinct genetic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886612.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


3. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M: Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A; 2008 Jan 22;105(3):1003-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with cagA-positive Helicobacter pylori is associated with gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma of B cell origin.
  • The cagA-encoded CagA protein is delivered into gastric epithelial cells via the bacterial type IV secretion system and, upon tyrosine phosphorylation by Src family kinases, specifically binds to and aberrantly activates SHP-2 tyrosine phosphatase, a bona fide oncoprotein in human malignancies.
  • Here, we generated transgenic mice expressing wild-type or phosphorylation-resistant CagA throughout the body or predominantly in the stomach.
  • Wild-type CagA transgenic mice showed gastric epithelial hyperplasia and some of the mice developed gastric polyps and adenocarcinomas of the stomach and small intestine.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14559-64 [10588744.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1229-42 [15887107.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):28-37 [11902583.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] Bioessays. 2003 Jun;25(6):542-53 [12766944.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Nat Med. 2004 Aug;10(8):849-57 [15273746.001]
  • [Cites] Blood. 2005 Jul 1;106(1):311-7 [15761018.001]
  • [Cites] Eur J Med Genet. 2005 Apr-Jun;48(2):81-96 [16053901.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1181-90 [16618412.001]
  • [Cites] Annu Rev Biochem. 2006;75:137-63 [16756488.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3462-72 [17160020.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1909-25 [15314019.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):688-94 [15343275.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26559-70 [8253786.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):160-4 [7816809.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] Am J Clin Pathol. 1996 Nov;106(5):670-5 [8929480.001]
  • [Cites] Trends Genet. 1996 May;12(5):171-5 [8984731.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Jan;280(1):225-31 [8996200.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5499-507 [9271425.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):375-9 [9517643.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4255-9 [9766647.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8816-20 [15604238.001]
  • [Cites] Blood. 2001 Feb 15;97(4):911-4 [11159516.001]
  • (PMID = 18192401.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori; 21820-51-9 / Phosphotyrosine
  • [Other-IDs] NLM/ PMC2242726
  •  go-up   go-down


Advertisement
4. Wu Y, Yao LQ, Cheng J, Tian H: [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):1069-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty patients were identified to have poorly differentiated adenocarcinomas, 6 had mucinous adenocarcinomas, 6 had mucinous carcinomas, 4 had poorly differentiated squamous cell carcinomas, and 2 had melanoma.
  • Immunohistochemistry identified the primary tumor sites in these cases, including 12 stomach cancers, 10 breast cancers, 8 prostate cancers, 4 lung cancers, 1 dorsal melanoma, 1 left foot melanoma, and 2 nasopharyngeal cancers.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Marrow Examination / methods. Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501396.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


5. Ushiku T, Shinozaki A, Uozaki H, Iwasaki Y, Tateishi Y, Funata N, Seto Y, Fukayama M: Gastric carcinoma with osteoclast-like giant cells. Lymphoepithelioma-like carcinoma with Epstein-Barr virus infection is the predominant type. Pathol Int; 2010 Aug;60(8):551-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric carcinoma with osteoclast-like giant cells. Lymphoepithelioma-like carcinoma with Epstein-Barr virus infection is the predominant type.
  • Osteoclast-like giant cells (OGC) are rare in gastric carcinomas.
  • Histopathological study of seven gastric carcinomas with OGC demonstrated three distinct types: lymphoepithelioma-like carcinoma (LELC), non-LELC, and giant cell tumor (GCT) types.
  • LELC is a poorly differentiated adenocarcinoma with prominent lymphoid stroma.
  • The LELC type (n = 4) showed similar histology to LELC of the stomach, except that they were accompanied by OGC and granulomatous reaction.
  • Both LELC and non-LELC types are included in the differential diagnosis of isolated granulomatous gastritis, and EBER-ISH was useful for the identification of LELC type.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Epstein-Barr Virus Infections / pathology. Giant Cells / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618732.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


6. Al-Moundhri MS, Al-Nabhani M, Tarantini L, Baccarelli A, Rusiecki JA: The prognostic significance of whole blood global and specific DNA methylation levels in gastric adenocarcinoma. PLoS One; 2010;5(12):e15585
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of whole blood global and specific DNA methylation levels in gastric adenocarcinoma.
  • BACKGROUND: Epigenetics, particularly DNA methylation, has recently been elucidated as important in gastric cancer (GC) initiation and progression.
  • METHODS: Genomic DNA was extracted from the peripheral blood of 105 Omani GC patients at diagnosis.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1511-6 [10995806.001]
  • [Cites] Int J Cancer. 2010 Oct 15;127(8):1866-74 [20099281.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):1002-4 [11606513.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):208-11 [11668499.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7959-63 [11691819.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):45-50 [11786397.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Int J Cancer. 2002 Jul 20;100(3):249-60 [12115538.001]
  • [Cites] IARC Sci Publ. 2002;156:79-83 [12484132.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):664-73 [12566312.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):370-1; author reply 371-3 [12819044.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3743-6 [12839968.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4158-66 [12874021.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] Mutat Res. 2003 Sep 29;530(1-2):9-17 [14563526.001]
  • [Cites] Histol Histopathol. 2004 Jan;19(1):221-8 [14702190.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):489-92 [14998854.001]
  • [Cites] IARC Sci Publ. 2004;(157):301-10 [15055303.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2477-81 [15330201.001]
  • [Cites] Gut. 1996 Sep;39(3):434-8 [8949650.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):171-5 [9085163.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63 [15701853.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):134-8; discussion 138 [15895454.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2190-4 [15942635.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1865-8 [16103427.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):974-80 [15986439.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):24-9 [16531765.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):859-67 [16406514.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):108-14 [17220338.001]
  • [Cites] Carcinogenesis. 2007 Aug;28(8):1745-51 [17522068.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):359-66 [18339581.001]
  • [Cites] PLoS One. 2008;3(7):e2656 [18628976.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jul-Aug;18(4):711-7 [17944913.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1566-71 [18711702.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8 [19033568.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):922-8 [19258481.001]
  • [Cites] Clin Chim Acta. 2009 Jun 27;404(2):128-33 [19336228.001]
  • [Cites] Int J Cancer. 2009 Aug 1;125(3):666-73 [19382179.001]
  • [Cites] Carcinogenesis. 2009 Nov;30(11):1889-97 [19584139.001]
  • [Cites] J Mol Diagn. 2010 Mar;12(2):177-83 [20093385.001]
  • [Cites] Br J Nutr. 2010 Jul;104(1):24-30 [20205967.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4238-43 [11358850.001]
  • (PMID = 21203466.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdh1 Proteins; 0 / Cell Cycle Proteins; 0 / Core Binding Factor Alpha 3 Subunit; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Fzr1 protein, mouse; 0 / Sulfites; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA; OJ9787WBLU / hydrogen sulfite
  • [Other-IDs] NLM/ PMC3009731
  •  go-up   go-down


7. Ramírez Ramos A, Sánchez Sánchez R: [Helicobacter pylori and gastric cancer]. Rev Gastroenterol Peru; 2008 Jul-Sep;28(3):258-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helicobacter pylori and gastric cancer].
  • Since its discovery and identification in gastric tissue by Marshall and Warren in 1983, our knowledge about the effects of Helicobacter pylori infection has grown considerably.
  • Its role in the multifactorial pathology of peptic ulcer disease (gastrodudodenal ulcer disease), gastric adenocarcinoma, and MALT lymphoma is now widely accepted while its involvement in extraintestinal disease is still controversial.The correlation between the colonization of the stomach by H. pylori and gastric lymphoma has been demonstrated in multiple studies.
  • Between 65 and 80% of distal gastric adenocarcinomas are attributed to H. pylori infection.
  • However, gastric carcinogenesis cannot be explained by H. pylori infection alone.
  • Among those individuals infected by this bacteria, only a small percentage (2-5%) ever develops gastric cancer, the majority exhibit benign lesions.
  • In this article, we conduct a review of the widely accepted theories regarding gastric cancer, Helicobacter pylori, the correlations and enigmas between them, the reported geographical variations, and the various proposed hypotheses on the carcinogenic mechanism of Helicobacter pylori.
  • [MeSH-major] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori. Lymphoma / etiology. Lymphoma, B-Cell, Marginal Zone / etiology. Stomach Neoplasms / etiology
  • [MeSH-minor] Diet. Humans. Risk Factors. Socioeconomic Factors. Stomach / microbiology. Virulence

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958142.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Peru
  • [Number-of-references] 29
  •  go-up   go-down


8. Jang TJ: The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol Res Pract; 2010 Jan 15;206(1):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer.
  • Persistent H. pylori-associated gastritis is closely associated with gastric carcinogenesis.
  • We investigated the number of Tregs in the context of H. pylori colonization in chronic gastritis, examined the relationship between it and histopathological findings and compared it with that of gastric dysplasia and adenocarcinoma.
  • This study was based on the analysis of gastric biopsy specimens from 126 cases of H. pylori-associated gastritis, 16 cases of H. pylori-negative gastritis, 17 cases of gastric dysplasia, and 25 cases of gastric adenocarcinoma.
  • It was significantly elevated in adenocarcinomas compared to chronic gastritis and gastric dysplasia.
  • In summary, the number of Tregs is increased in H. pylori-associated gastritis and gastric cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Forkhead Transcription Factors / immunology. Gastritis / immunology. Helicobacter Infections / immunology. Helicobacter pylori / immunology. Stomach Neoplasms / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Cell Count. Child. Female. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19819643.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


9. Sharma A, Nitharwal RG, Singh B, Dar A, Dasgupta S, Dhar SK: Helicobacter pylori single-stranded DNA binding protein--functional characterization and modulation of H. pylori DnaB helicase activity. FEBS J; 2009 Jan;276(2):519-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori, an important bacterial pathogen, causes gastric ulcer and gastric adenocarcinoma in humans.


10. Azem J, Svennerholm AM, Lundin BS: B cells pulsed with Helicobacter pylori antigen efficiently activate memory CD8+ T cells from H. pylori-infected individuals. Clin Immunol; 2006 Feb-Mar;118(2-3):284-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori infection causes chronic gastritis that may progress to peptic ulcers or gastric adenocarcinoma and thereby cause major world-wide health problems.
  • We further show that the majority of CD8+ T cells in H. pylori-infected gastric mucosa are memory cells, and that memory CD8+ T cells sorted from peripheral blood of H. pylori-infected individuals respond 15-fold more to H. pylori urease compared to memory cells from uninfected subjects.
  • [MeSH-minor] Adult. Cell Proliferation. Cells, Cultured. Gastric Mucosa / immunology. Gastric Mucosa / microbiology. Humans. Middle Aged. Monocytes / immunology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324887.001).
  • [ISSN] 1521-6616
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  •  go-up   go-down


11. Sargan I, Motoc A, Vaida MA, Bolintineanu S, Vîscu S: Anatomic and pathological aspects in the pathology of malignant gastric tumors. Rom J Morphol Embryol; 2006;47(2):163-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic and pathological aspects in the pathology of malignant gastric tumors.
  • Efforts in perfecting the methods of early diagnosis, in trying to assess premalignant conditions, and in properly staging malignant tumors are still in trend.
  • The geographic area around Timişoara (Banat Region) is situated on the first place in the country as far as the gastric location of cancer is concerned.
  • The authors aimed to deal with the initial stage in the development of gastric cancer, a stage which has been oncologically termed "precancerous damage", and with the neoplastic invasion of the gastric wall.
  • The present paper is based on the 1995-2005 statistics of the IInd Surgical Department of the Timişoara County Hospital, the study group consisting of 802 patients admitted for gastric disorders, 522 of which being later diagnosed with a tumoral pathology.
  • The age for gastric tumoral pathology ranged between 36-88 years in females, and 31-87 years in males.
  • Most gastric carcinomas are adenocarcinoma, 404 (90%) cases--could be classified as follows: 167 cases of tubular adenocarcinoma; 39 cases of papillary adenocarcinoma; 24 cases of mucinous or colloid adenocarcinoma; 141 "signet ring"-cell carcinoma; 33 cases of undifferentiated carcinoma.
  • Attention should be given to precancerous conditions; there was a large number of premalignant or potentially malignant gastric damage: atrophic chronic gastritis (54 cases), intestinal metaplasia (104 cases), and gastric dysplasia (104 cases).
  • [MeSH-major] Precancerous Conditions / pathology. Stomach / anatomy & histology. Stomach / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy. Female. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106525.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


12. Khan AZ, Miles WF, Singh KK: Initial experience with laparoscopic bypass for upper gastrointestinal malignancy: a new option for palliation of patients with advanced upper gastrointestinal tumors. J Laparoendosc Adv Surg Tech A; 2005 Aug;15(4):374-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various interventions have been described for the palliation of biliary and gastric outlet obstruction including open surgery, endoscopic and transparietal stent placement.
  • PATIENTS AND METHODS: Between August 2000 and April 2002 laparoscopic gastric and biliary bypass concurrently or alone was attempted in 19 consecutive patients with unresectable carcinoma of the head of the pancreas, adenocarcinoma of the stomach, cholangiocarcinoma of the distal common bile duct, or adenocarcinoma of the duodenum.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108739.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A: Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? Dig Dis Sci; 2009 May;54(5):1015-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?
  • The aim of this study was to investigate whether cyclin E, pRb, and p21 can be used as prognostic indicators in gastric cancer.
  • MATERIAL AND METHODS: Fifty-six patients with gastric adenocarcinoma, who underwent curative resection, constituted the group of our study.
  • Positive pRb immunostaining was found in 24 (42.9%) cases and it was associated with the absence of Helicobacter pylori (P=0.044), whereas positive p21 immunostaining was found in 21 tumors (37.5%) and it was associated with less depth of gastric wall infiltration (P=0.001), the absence of lymphatic (P=0.019) and vascular infiltration (P=0.024), and the absence of liver metastasis (P=0.044).
  • CONCLUSION: The expression of cyclin E could not predict the survival in this series of patients with gastric cancer, whereas the expression of pRb and p21 was associated with a favorable prognosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Gastrectomy. Oncogene Proteins / analysis. Retinoblastoma Protein / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1999 Apr;25(2):157-63 [10218458.001]
  • [Cites] Ann Surg. 1997 Jul;226(1):35-42 [9242335.001]
  • [Cites] Cancer Lett. 2000 May 29;153(1-2):129-36 [10779641.001]
  • [Cites] Br J Cancer. 1997;75(11):1617-20 [9184177.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1276-82 [14691913.001]
  • [Cites] Cancer Lett. 2000 Feb 1;148(2):181-8 [10695995.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4215-20 [10628377.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):963-9 [11029499.001]
  • [Cites] Kurume Med J. 2000;47(3):199-203 [11059220.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):405-14 [16270527.001]
  • [Cites] J Korean Med Sci. 1998 Oct;13(5):513-8 [9811181.001]
  • [Cites] J Pathol. 1999 Oct;189(2):186-93 [10547573.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):625-9 [9310133.001]
  • [Cites] Korean J Intern Med. 2005 Mar;20(1):1-7 [15906946.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):617-21 [7559076.001]
  • [Cites] Eur J Surg Oncol. 2000 Feb;26(1):39-43 [10718178.001]
  • [Cites] Oncology. 2002;63(4):353-61 [12417790.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1447-53 [15746045.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):585-94 [10666388.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1238-43 [9529014.001]
  • [Cites] Gastric Cancer. 1998 Mar 1;1(2):160-165 [11957061.001]
  • [Cites] Histopathology. 2003 Jan;42(1):66-9 [12493027.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • [Cites] J Exp Ther Oncol. 1996 Mar;1(2):88-94 [9414392.001]
  • [Cites] Chin Med J (Engl). 2003 Jan;116(1):20-3 [12667381.001]
  • [Cites] Scand J Gastroenterol. 2001 Sep;36(9):975-80 [11521990.001]
  • (PMID = 19058005.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCNE1 protein, human; 0 / CDKN1A protein, human; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Oncogene Proteins; 0 / Retinoblastoma Protein
  •  go-up   go-down


14. Lee SH, Ryu CB, Jang JY, Cho JY: [Magnifying endoscopy in upper gastrointestinal tract]. Korean J Gastroenterol; 2006 Sep;48(3):145-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the diagnosis of upper gastrointestinal (GI) lesions, magnification method is usually used in conjunction with chromoscopy, enabling the endoscopist to view subtle mucosal patterns in exquisite detail.
  • Recently published datas have shown that magnifying endoscopy might be a valuable adjunct for the diagnosis, detection, and characterization of inflammatory and neoplastic lesions of the upper GI tract.
  • It is also proven to be an useful surveillance protocol in identifying dysplastic epithelium or early cancer within a segment of Barrett's esophagus.
  • Possible indications for magnifying endoscopy in upper GI tract include screening and surveillance of Barrett's esophagus, defining the extent of esophageal and gastric adenocarcinoma, detecting synchronous/metachronous gastric and esophageal cancers, diagnosing Helicobacter pylori infection, and recognizing minimal mucosal changes in gastroesophageal reflux disease.
  • [MeSH-minor] Diagnosis, Differential. Duodenal Diseases / pathology. Esophageal Diseases / pathology. Humans. Stomach Diseases / pathology. Upper Gastrointestinal Tract / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047429.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 26
  •  go-up   go-down


15. Pazos Y, Alvarez CJ, Camiña JP, Casanueva FF: Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway. FEBS J; 2007 Nov;274(21):5714-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway.
  • The present study analyzes the molecular steps involved in the full lysophosphatidic acid (LPA) receptor-mediated activation of the mitogenic extracellular signal-regulated kinase (ERK) pathway and its consequent role as an inhibitor of ghrelin secretion in the gastric adenocarcinoma cell line AGS.
  • Finally, a correlation was observed between the mitogenic effects of LPA and ghrelin secretion in the human gastric adenocarcinoma cell line AGS.
  • [MeSH-major] Adenocarcinoma / metabolism. Ghrelin / metabolism. Lysophospholipids / pharmacology. MAP Kinase Signaling System. Stomach Neoplasms / metabolism


16. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M, Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R: Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst; 2008 Mar 19;100(6):388-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
  • BACKGROUND: Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor.
  • METHODS: Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV (T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m(2), on days 1 and 5], epirubicin [30 mg/m(2), days 1 and 5], L-leucovorin [100 mg/m(2), days 1-4], and 5-fluorouracil [300 mg/m(2), days 1-4] in a hospital setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Gastrectomy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2008 Mar 19;100(6):376-7 [18334705.001]
  • (PMID = 18334706.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEP protocol
  •  go-up   go-down


17. Hoshihara Y, Kogure T, Yamamoto T, Hashimoto M, Hoteya O: [Endoscopic diagnosis of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1394-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic diagnosis of Barrett's esophagus].
  • The prevalence of Barrett's esophagus and Barrett's adenocarcinoma is very low.
  • But in Western countries Barrett's mucosa is defined as CLE with intestinal metaplasia, and many cases of Barrett's esophagus and Barrett's adenocarcinoma are reported.
  • The definite endoscopic diagnosis of Barrett's mucosa cannot be so easy.
  • In no cases were the longitudinal vessels observed under the gastric mucosa beyond the esophageal hiatus.
  • It is peculiar to the esophagus to be able to observe subepithelial longitudinal vessels in the vicinity of the esophago-gastric junction.
  • When longitudinal vessels are found only under the columnar epithelium at the oral side over the esophageal hiatus from the stomach, this indicates Barrett's epithelium.
  • Thus the definite diagnosis of Barrett's epithelium can be made by endoscopy.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Endoscopy, Gastrointestinal

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101228.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


18. Wang R, Ciren YJ, Yang JL, Zhang B, Chen JP, Tang CW: [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov;40(6):1029-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene].
  • OBJECTIVE: To investigate the effect of cyclooxygenase2 inhibitor celecoxib on the suppression of human gastric cancer (GC) growth and the induction of nonsteroidal anti-inflammatory drug activated gene (NAG-1) expression.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Growth Differentiation Factor 15 / metabolism. Pyrazoles / therapeutic use. Stomach Neoplasms / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067113.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15; 0 / Pyrazoles; 0 / RNA, Messenger; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


19. Giglio P, Weinberg JS, Forman AD, Wolff R, Groves MD: Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer; 2005 Jun 1;103(11):2355-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract.
  • RESULTS: The patient population was composed of patients with gastric adenocarcinoma (n = 8 patients), esophageal adenocarcinoma (n = 7 patients), colon and/or rectal adenocarcinoma (n = 5 patients), and pancreatic adenocarcinoma (n = 1 patient).
  • The median overall survival after the initial diagnosis of adenocarcinoma was 55 weeks (range, 8-884 wks), and the median survival after the diagnosis of NM was 7 weeks (range, 0-64 wks).
  • No factors identified had an impact on outcome, including symptoms, physical findings at diagnosis, imaging characteristics, or cerebrospinal fluid findings.
  • CONCLUSIONS: Patients with NM from GI tract adenocarcinomas universally had poor outcomes.
  • [MeSH-major] Adenocarcinoma / secondary. Gastrointestinal Neoplasms / pathology. Meningeal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856426.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


20. Yoshizawa M, Osawa H, Yamamoto H, Kita H, Nakano H, Satoh K, Shigemori M, Tsukui M, Sugano K: Diagnosis of elevated-type early gastric cancers by the optimal band imaging system. Gastrointest Endosc; 2009 Jan;69(1):19-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of elevated-type early gastric cancers by the optimal band imaging system.
  • BACKGROUND: The endoscopic diagnosis of an elevated-type early gastric cancer is often difficult.
  • OBJECTIVE: To evaluate whether the OBI system facilitates detection of the demarcation lines between an elevated-type early gastric cancer and surrounding tissue and thus is more helpful for performing endoscopic therapy.
  • PATIENTS: Seventy-five patients, 81 lesions with an elevated-type early gastric cancer.
  • MAIN OUTCOME MEASUREMENTS: A comparison between OBI images and conventional endoscopic images in the identification of the demarcation lines of an elevated-type early gastric cancer without magnification and the rate of success in identifying the abnormal surface structure of cancer by using low-magnified OBI images.
  • With 40-fold magnification, irregular microstructural or nonstructural patterns were also found within cancer lesions in all cases studied but in none of the cases in the surrounding noncancerous mucosa.
  • CONCLUSIONS: The new contrast images obtained with the OBI system enable better determination of the demarcation lines of elevated-type early gastric cancers, and this system may be useful for performing endoscopic therapy of this type of cancer as a new endoscopic modality.
  • [MeSH-major] Adenocarcinoma / pathology. Gastric Mucosa / pathology. Gastroscopy / methods. Image Enhancement / instrumentation. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Confidence Intervals. Early Diagnosis. Female. Gastroscopes. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Probability. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111685.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H: Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett; 2005 Jan 20;217(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of intestinal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter.
  • Tandem repeat number polymorphism of a CCTTT pentanucleotide in the promoter region of the inducible nitric oxide synthase gene (iNOS) and a polymorphism of the interleukin-1beta (IL-1B) promoter at position -31 were analyzed in DNA samples from 181 Japanese control subjects and 158 gastric cancer patients, including 96 intestinal type and 62 diffuse type.
  • An association between the intestinal type of gastric adenocarcinoma and higher promoter activity of the iNOS gene was found in women, especially those having higher promoter activity of the IL-1B gene and without a history of smoking.
  • Our results imply that chronic inflammation caused by excess nitric oxide generated by iNOS contributes to Helicobacter pylori-induced gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats / genetics. Nitric Oxide Synthase / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617837.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-1; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


22. Ibáñez FJ, Azagra JS, Goergen M, Bordas JM, Almendral ML, Erro JM: [Laparoscopic surgery of gastric cancer]. An Sist Sanit Navar; 2005;28 Suppl 3:21-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery of gastric cancer].
  • INTRODUCTION: The present state of minimally invasive surgery in gastric cancer is reviewed and its technical aspects are detailed.
  • In this study involving 101 patients with gastric adenocarcinoma, the mini-invasive laparoscopic approach was employed as a surgical tool with the "aim of treatment by laparoscopy".
  • CONCLUSIONS: Laparoscopic gastrectomy associated with any type of lymphadenectomy is a significant but safe intervention, with acceptable rates of morbidity and mortality in patients with advanced gastric cancer, who frequently present a bad general status.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Laparoscopy. Stomach Neoplasms / surgery. Video-Assisted Surgery
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Laparotomy. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prospective Studies. Stomach / pathology. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16511576.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


23. Yu JC, Zhou H, Bai J, Yu Y, Geng JS, Qi JP, Fu SB: Human gastric adenocarcinoma allelotype on chromosomes 17 and 18. J Int Med Res; 2008 Mar-Apr;36(2):279-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human gastric adenocarcinoma allelotype on chromosomes 17 and 18.
  • Allelic losses of multiple chromosome loci in gastric adenocarcinoma suggest that inactivation of tumour suppressor genes in these regions may be important for tumourigenesis.
  • To define deletion intervals and find candidate tumour suppressor genes involved in gastric adenocarcinoma pathogenesis, a genome-wide search for loss of heterozygosity (LOH) was conducted in 45 patients with primary gastric adenocarcinoma.
  • LOH mapping showed allelic losses were widespread on both chromosomes and suggests the possibility that multiple tumour suppressor genes, including one or more that are unknown, might be inactivated in the aetiology of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Alleles. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 18 / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380938.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Johnson AH, Frierson HF, Zaika A, Powell SM, Roche J, Crowe S, Moskaluk CA, El-Rifai W: Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am J Pathol; 2005 Aug;167(2):577-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis.
  • Trefoil factor-1 (Tff1) expression is remarkably down-regulated in nearly all human gastric cancers.
  • Therefore, we used the Tff1 knockout mouse model to detect molecular changes in preneoplastic gastric dysplasia.
  • Oligonucleotide microarray gene expression analysis of gastric dysplasia of Tff1-/- mice was compared to that of normal gastric mucosa of wild-type mice.
  • Quantitative real-time reverse transcriptase-polymerase chain reaction and immunohistochemistry showed that Cldn7 was overexpressed in all 10 Tff1-/- gastric dysplasia samples.
  • Comparison with our serial analysis of gene expression database of human gastric cancer revealed similar deregulation in human gastric cancers.
  • Quantitative real-time reverse transcriptase-polymerase chain reaction of human gastric adenocarcinoma samples indicated that, of these three genes, CLDN7 was the most frequently up-regulated gene.
  • Using immunohistochemistry, both mouse and human gastric glands overexpressed Cldn7 in dysplastic but not surrounding normal glands.
  • Cldn7 expression was observed in 30% of metaplasia, 80% of dysplasia, and 70% of gastric adenocarcinomas.
  • Interestingly, 82% of human intestinal-type gastric adenocarcinomas expressed Cldn7 whereas diffuse-type gastric adenocarcinomas did not (P < 0.001).
  • These results suggest that Cldn7 expression is an early event in gastric tumorigenesis that is maintained throughout tumor progression.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1091-9 [11007946.001]
  • [Cites] J Pathol. 1999 Jul;188(3):312-7 [10419601.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:129-35 [11193568.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):285-93 [11283726.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6996-7001 [11585723.001]
  • [Cites] Genome Res. 2001 Oct;11(10):1686-98 [11591645.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2625-9 [11980659.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] J Cell Biol. 2002 May 27;157(5):761-70 [12034770.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4061-4 [12124342.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):655-9 [12168114.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1319-26 [12379766.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1187-97 [12615962.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:5-11 [12772880.001]
  • [Cites] Int J Mol Med. 2003 Jul;12(1):3-9 [12792801.001]
  • [Cites] Nat Cell Biol. 2003 Jul;5(7):595-7 [12833061.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] J Membr Biol. 2003 Aug 1;194(3):187-97 [14502431.001]
  • [Cites] Med Electron Microsc. 2003 Sep;36(3):147-56 [14505058.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2184-91 [14601088.001]
  • [Cites] Sci STKE. 2004 Jan 20;2004(216):pe2 [14734784.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Science. 1996 Oct 11;274(5285):259-62 [8824193.001]
  • [Cites] Bioinformatics. 2000 Jul;16(7):650-1 [11038335.001]
  • (PMID = 16049341.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093999; United States / NCI NIH HHS / CA / CA93999
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN7 protein, human; 0 / Claudins; 0 / DNA-Binding Proteins; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Estrogens; 0 / Growth Inhibitors; 0 / Immediate-Early Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / TFF1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / epithelial membrane protein-1
  • [Other-IDs] NLM/ PMC1603560
  •  go-up   go-down


25. Costantini R, De Nicola P, Bianco F, Cotroneo AR, Iezzi R, Di Bartolomeo N, Innocenti P: Tumor vs non-tumor origin of occult and obscure gastrointestinal bleeding requiring hospitalization. Tumori; 2007 Sep-Oct;93(5):461-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-five cases of obscure and 27 cases of occult bleeding were examined; all received a definite diagnosis during hospitalization.
  • In the cases with obscure bleeding the diagnosis was inflammatory bowel disease (n = 7), angiodysplasia (5 gastric, 2 duodenal, 2 jejunal, 3 ileal, 4 right colon), small bowel tumors (4 non-Hodgkin lymphomas, 1 leiomyoma, 6 adenocarcinomas), and gastric metaplasia of Meckel's diverticulum (n = 1).
  • Intestinal resections were performed for all small bowel tumors (8 laparotomic, 3 laparoscopic), 5 angiodysplasias, all cases of inflammatory bowel disease and gastric metaplasia of Meckel's diverticulum; arterial embolization was performed for 11 angiodysplasias.
  • In the cases with occult bleeding the diagnosis was sigmoid colon polyps in 6 (treatment, endoscopic polypectomy) and right colon cancer in 21 (treatment, right hemicolectomy).
  • Thanks to modern technology, however, their diagnosis and treatment can nowadays be promptly and successfully achieved.
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Intestinal Neoplasms / diagnosis. Occult Blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capsules. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Follow-Up Studies. Humans. Intestine, Small / pathology. Male. Middle Aged. Treatment Outcome. Videotape Recording

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038878.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsules
  •  go-up   go-down


26. Molina Infante J, Hernández Alonso M, Martín Noguerol E, Pérez Gallardo B, Dueñas Sadornil C: [Alopecia areata as the initial paraneoplastic presentation of gastric adenocarcinoma]. Gastroenterol Hepatol; 2009 Feb;32(2):128-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alopecia areata as the initial paraneoplastic presentation of gastric adenocarcinoma].
  • [Transliterated title] Alopecia areata como presentación inicial paraneoplásica de un adenocarcinoma gástrico.
  • [MeSH-major] Adenocarcinoma / complications. Alopecia Areata / etiology. Paraneoplastic Syndromes / etiology. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Alopecia Areata.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231692.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


27. Rocha FT, Lourenço LG, Jucá MJ, Costa V, Leal AT: Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy. Acta Cir Bras; 2009 May-Jun;24(3):189-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention by celecoxib in reflux-induced gastric adenocarcinoma in Wistar rats that underwent gastrojejunostomy.
  • PURPOSE: To evaluate chemoprevention by celecoxib in cases of reflux-induced gastric adenocarcinoma, in Wistar rats that underwent gastrojejunostomy.
  • Changes in the mucosa of the gastric body of group 1 and in the gastrojejunal anastomosis of groups 2 and 3, observed in histopathological and immunohistochemical examinations, were compared.
  • RESULTS: Comparison between groups 2 and 3 relative to the presence of adenocarcinoma showed a statistically significant difference (p=0.0023).
  • CONCLUSION: Celecoxib had an inhibiting effect on gastric carcinogenesis induced by enterogastric reflux in an animal model.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504000.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


28. Hur H, Kim JY, Cho YK, Han SU: Technical feasibility of robot-sewn anastomosis in robotic surgery for gastric cancer. J Laparoendosc Adv Surg Tech A; 2010 Oct;20(8):693-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technical feasibility of robot-sewn anastomosis in robotic surgery for gastric cancer.
  • BACKGROUND: Although several studies have reported on the feasibility of robot-assisted gastric cancer surgery using the da Vinci surgical system, reconstruction techniques have depended on staplers or hand sewing through minilaparotomy.
  • AIM: The aim of this study is to report on the feasibility of reconstruction methods using a robot-sewing technique in robotic surgery for treatment of gastric cancer.
  • PATIENT AND METHODS: Between January and April 2010, 7 patients in whom gastric adenocarcinoma was diagnosed underwent robotic surgery including robot-sewn anastomosis.
  • One patient was readmitted for stasis in the remnant stomach but conservatively recovered.
  • CONCLUSIONS: A robot-sewn anastomosis for reconstruction in robotic surgery for gastric cancer was feasible regardless of the reconstruction method.
  • [MeSH-major] Adenocarcinoma / surgery. Anastomosis, Surgical / methods. Robotics. Stomach Neoplasms / surgery. Suture Techniques

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809816.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shiozaki A, Miyazaki H, Niisato N, Nakahari T, Iwasaki Y, Itoi H, Ueda Y, Yamagishi H, Marunaka Y: Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci; 2006 Dec;56(6):401-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state.
  • The aim of the present study was to investigate whether an NKCC blocker affects cancer cell growth.
  • We found that poorly differentiated gastric adenocarcinoma cells (MKN45) expressed the mRNA of NKCC1 three times higher than moderately differentiated ones (MKN28) and that the NKCC in MKN45 showed higher activity than that in MKN28.
  • Using flow cytometrical analysis, we found that the exposure to furosemide brought MKN45 cells to spend more time at the G(0)/G(1) phase, but not MKN28 cells.
  • Based on these observations, we indicate that furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Proliferation / drug effects. Furosemide / pharmacology. Sodium Potassium Chloride Symporter Inhibitors / pharmacology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858893 for PMID:17052386 [PharmGKB] .
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052386.001).
  • [ISSN] 1880-6546
  • [Journal-full-title] The journal of physiological sciences : JPS
  • [ISO-abbreviation] J Physiol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Sodium Potassium Chloride Symporter Inhibitors; 0 / Sodium-Potassium-Chloride Symporters; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


30. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol; 2006 Aug 20;24(24):3953-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
  • PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal.
  • PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible.
  • CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting.
  • With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921048.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


31. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study.
  • The diagnosis of gastric epithelial dysplasia, a precursor lesion of gastric adenocarcinoma, is hindered by interobserver variability and by its resemblance to regenerative changes.
  • Loss of cell polarity, a histological feature of gastric epithelial dysplasia, may be difficult to ascertain, especially in the setting of inflammation or injury.
  • A biomarker of cell polarity could be useful in diagnosis of dysplasia, but has not been reported.
  • Two homologs, lgl1 and lgl2, are present in mammals and lgl2 mRNA is highly expressed in the stomach.
  • The goal of our study was to test the hypothesis that Lgl2 protein expression and/or localization are disrupted in gastric epithelial dysplasia and adenocarcinoma.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • All normal, reactive, and chronically inflamed gastric epithelia showed basolateral Lgl2 staining.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • All but one case each of gastric epithelial dysplasia and adenocarcinoma showed either complete loss of anti-Lgl2 immunoreactivity or diffuse, mostly weak, cytoplasmic staining.
  • Complete loss of immunoreactivity was significantly more often observed in diffuse-type than in intestinal-type adenocarcinomas (79 vs 48%, respectively).
  • Our data suggest that Lgl2 expression is either aberrantly localized or lost in gastric epithelial dysplasia and adenocarcinoma, whereas it is maintained in reactive gastric mucosa.
  • We propose that Lgl2 may be a potential marker to rule out gastric epithelial dysplasia and adenocarcinoma in diagnostic specimens.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


32. Kutup A, Yekebas EF, Izbicki JR: Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res; 2010;182:115-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third.
  • Esophageal and gastric cancers are aggressive neoplasms with a poor prognosis.
  • The potential role and -benefit of an antibody-based treatment as a therapeutic target would be of particular interest in tumors with a notoriously poor prognosis such as esophageal cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676876.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


33. Di Bartolomeo M, Buzzoni R, Mariani L, Ferrario E, Katia D, Gevorgyan A, Zilembo N, Bordonaro R, Bochicchio AM, Massidda B, Ardizzoia A, Marini G, Aitini E, Schieppati G, Comella G, Pinotti G, Palazzo S, Cicero G, Bajetta E, Italian Trial in Medical Oncology (ITMO) Group, Villa E, Fagnani D, Reguzzoni G, Agostana B, Oliani C, Kildani B, Duro M, Botta M, Mozzana R, Mantovani G: Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Oncology; 2006;71(5-6):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
  • OBJECTIVE: Combination therapies of fluorouracil (FU) with irinotecan (CPT-11) and docetaxel plus cisplatin have been proven to be active in metastatic gastric cancer.
  • METHODS: 169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B).
  • All patients had histologically confirmed gastric carcinoma with nodal positivity or pT3/4.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • [ErratumIn] Oncology. 2007;73(5-6):406. Ardizzoni, Antonio [corrected to Ardizzoia, Antonio]
  • (PMID = 17855795.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


34. Trejo-de la O A, Torres J, Pérez-Rodríguez M, Camorlinga-Ponce M, Luna LF, Abdo-Francis JM, Lazcano E, Maldonado-Bernal C: TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol; 2008 Nov;129(2):333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori is associated with peptic ulcer and gastric adenocarcinoma.
  • We aimed to evaluate the association of TLR2/R753Q and TLR4/D299G/T399I SNPs with gastroduodenal diseases; and study the effect of SNPs on cytokine and chemokine expression in the gastric mucosa.
  • TLR4/D299G/T399I polymorphisms were more frequent in duodenal ulcer and showed a trend in gastric cancer, when compared with non-atrophic gastritis.
  • SNPs in TLR4 gene had an association with severe H. pylori-associated disease and with modified pattern of inflammatory cytokines and chemokines in the gastric mucosa.
  • [MeSH-major] Chemokines / analysis. Cytokines / analysis. Duodenal Ulcer / genetics. Gastritis / genetics. Helicobacter Infections / complications. Helicobacter pylori. Polymorphism, Single Nucleotide. Stomach Neoplasms / genetics. Toll-Like Receptor 2 / genetics. Toll-Like Receptor 4 / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755634.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / TLR2 protein, human; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4
  •  go-up   go-down


35. Lee SW, Kang SB, Kim YS, Nam SW, Lee DS, Lee HK, Han SW: [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2007 Mar;49(3):152-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma].
  • BACKGROUND/AIMS: The aim of this study was to investigate the immunohistochemical overexpression of c-erbB-2 and c-met proteins according to the histopathological parameters such as grade of dysplasia, histological type, depth of invasion, lymph node metastasis, and TNM stage in gastric adenoma and gastric adenocarcinoma.
  • METHODS: Immunohistochemical staining using monoclonal c-erbB-2 and c-met antibodies was performed on paraffin embedded specimens in 43 adenomas and 44 adenocarcinomas.
  • RESULTS: The expression rate of c-erbB-2 was higher in adenomas (91%) than adenocarcinomas (30%).
  • The expression rate of c-met was higher in adenocarcinomas (77%) than adenomas (49%).
  • In adenocarcinoma, c-met expression was significantly related with lymph node metastasis.
  • CONCLUSIONS: c-erbB-2 would be involved in the development of relatively early stage gastric carcinogenesis. c-erbB-2 is related with histologic type and c-met with lymph node metastasis in gastric carcinomas.
  • Although meaning for the expression of these proteins in gastric carcinomas would be different, these proteins may play as important oncogenes in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-met / metabolism. Receptor, ErbB-2 / metabolism. Stomach Neoplasms / metabolism


36. Ishiura Y, Yamamoto H, Terasaki Y, Ishida Y, Yokawa S, Fukushima W, Hirosawa H, Izumi R, Kodama K, Motoi I, Tanikawa F, Ichihashi K, Maruyama K, Miyazu M, Yoneda K, Saito K, Kasahara K, Fujimura M: [A case of synchronous triple cancer involving lung, stomach and bladder, responding to combination chemotherapy of S-1 and cisplatin]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1395-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous triple cancer involving lung, stomach and bladder, responding to combination chemotherapy of S-1 and cisplatin].
  • Succeeding upper gastro-intestinal fiberscopy and cystoscopy revealed poorly-differentiated adenocarcinoma of the stomach and urothelial carcinoma of the bladder.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use. Urinary Bladder Neoplasms / drug therapy


37. Qureshi WA, Wu J, Demarco D, Abudayyeh S, Graham DY: Capsule endoscopy for screening for short-segment Barrett's esophagus. Am J Gastroenterol; 2008 Mar;103(3):533-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The rise in the incidence of esophageal adenocarcinoma has led to the development of new methods to screen for the precursor lesion, Barrett's esophagus.
  • RESULTS: Twenty patients were studied; in 18, the capsule passed into the stomach.
  • [MeSH-major] Barrett Esophagus / diagnosis. Capsule Endoscopy
  • [MeSH-minor] Aged. Esophagoscopy. Hernia, Hiatal / diagnosis. Humans. Male. Middle Aged. Observer Variation

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047544.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Long KB, Hornick JL: SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol; 2009 Dec;40(12):1768-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SOX2 is a high-mobility group box embryonic stem cell transcription factor that is expressed in the developing foregut and normal gastric epithelium and is downregulated in intestinal metaplasia of the stomach and esophagus.
  • The purpose of this study was to determine whether SOX2 is differentially expressed in squamous cell carcinomas versus adenocarcinomas of the esophagus and rectum/anal canal and to compare its expression to p63, cytokeratin 5/6, and CDX2.
  • In total, 93 tumors were evaluated: 26 esophageal squamous cell carcinomas, 23 esophageal adenocarcinomas, 21 squamous cell carcinomas of the anal canal, and 23 rectal adenocarcinomas.
  • SOX2 was expressed in 81% of esophageal squamous cell carcinomas and 91% of anal canal squamous cell carcinomas, compared to 13% and 17% of esophageal and rectal adenocarcinomas, respectively. p63 was expressed in 96% of esophageal squamous cell carcinomas and 100% of anal canal squamous cell carcinomas; the single squamous cell carcinoma negative for p63 was strongly positive for SOX2.
  • Cytokeratin 5/6 was expressed in most esophageal and anal canal squamous cell carcinomas, but was also positive in 43% of esophageal adenocarcinomas and 13% of rectal adenocarcinomas.
  • In summary, SOX2 is preferentially expressed in squamous cell carcinomas of the esophagus and anal canal compared to adenocarcinomas from these sites.
  • SOX2 may be useful in an immunohistochemical panel to differentiate between squamous cell carcinomas and adenocarcinomas of the gastrointestinal tract.
  • [MeSH-minor] Adenocarcinoma / metabolism. Diagnosis, Differential. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / CKAP4 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  •  go-up   go-down


39. Perrone M, Muñoz L, Camorlinga M, Correnti M, Cavazza ME, Lecuna V, Torres J: [Importance of IgG anti-CagA antibodies of Helicobacter pylori in Venezuelan patients with gastric diseases]. Invest Clin; 2005 Dec;46(4):357-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of IgG anti-CagA antibodies of Helicobacter pylori in Venezuelan patients with gastric diseases].
  • [Transliterated title] Importancia de la respuesta humoral de IgG anti-CagA de Helicobacter pylori en pacientes venezolanos con enfermedades de las vías digestivas superiores.
  • It is associated with chronic gastritis, peptic ulcer disease and constitutes a major risk factor for gastric adenocarcinoma and lymphoma.
  • We evaluated 66 patients from the Hospital Universitario de Caracas, attending in the gastroscopy service. H. pylori infection was detected by culture and rapid urease test.
  • The positive rates of CagA antibodies in patients with gastric ulcer, gastric cancer and chronic gastritis were 87.8%, 77.7% y 40.8% respectively.
  • The serum antibodies anti-CagA were similar between peptic ulcer disease and gastric cancer patients.
  • [MeSH-major] Antigens, Bacterial / immunology. Bacterial Proteins / immunology. Immunoglobulin G / immunology. Stomach Diseases / immunology. Stomach Diseases / microbiology

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353543.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Venezuela
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Immunoglobulin G; 0 / cagA protein, Helicobacter pylori; EC 3.5.1.5 / Urease
  •  go-up   go-down


40. Moenig SP, Luebke T, Baldus SE, Schroeder W, Bollschweiler E, Schneider PM, Hoelscher AH: Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases. Anticancer Res; 2005 Mar-Apr;25(2B):1349-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases.
  • BACKGROUND: The feasibility and diagnostic reliability of sentinel lymph node biopsy of gastric carcinoma are still unclear and controversial.
  • PATIENTS AND METHODS: To assess the applicability of the sentinel node concept to gastric carcinoma, we retrospectively analyzed the location of metastatic lymph nodes in patients with only one or two lymph node metastases.
  • RESULTS: A total of 135 patients, who underwent gastrectomy with D2 lymphadenectomy for primary gastric adenocarcinoma between 1997 and 2001, were enrolled in this study.
  • Skip metastases were only seen in one patient with cardia carcinoma and lymph node involvement of compartment II (left gastric artery).
  • CONCLUSION: In patients with gastric carcinoma, especially in early stage carcinoma, the phenomenon of skip metastasis is infrequent.
  • Therefore, the sentinel node concept may be feasible in gastric cancer.
  • [MeSH-major] Sentinel Lymph Node Biopsy. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865090.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


41. Wu WK, Shin VY, Ye YN, Wong HP, Huang FY, Hui MK, Lam EK, Cho CH: Heparin increases human gastric carcinoma cell growth. Anticancer Res; 2006 Jan-Feb;26(1A):439-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparin increases human gastric carcinoma cell growth.
  • BACKGROUND: Heparin has been widely used to prevent cancer-associated thromboembolism in cancer patients.
  • Recent evidence reveals that heparin could modulate cell proliferation in the stomach.
  • The effect of heparin on gastric cancer growth, however, is unknown.
  • The effect of heparin on the proliferation of a human gastric adenocarcinoma cell line, BGC-823, was investigated.
  • RESULTS: Heparin significantly increased cell proliferation in BGC-823 cancer cells by 15.5% at the dose of 0.2 microg/ml.
  • CONCLUSION: Our results suggest that heparin can promote the proliferation and up-regulation of c-Myc protein expression in gastric cancer cells.
  • [MeSH-major] Heparin / pharmacology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475731.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 9005-49-6 / Heparin; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


42. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis; 2005 Oct;26(10):1698-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas.
  • Recent studies indicate that the hedgehog pathway activation occurs in the stomach and other gastrointestinal cancers.
  • Here, we report our findings that the elevated expression of hedgehog target genes human patched gene 1 (PTCH1) or Gli1 occurs in 63 of the 99 primary gastric cancers.
  • The sonic hedgehog (Shh) transcript is localized to the cancer tissue, whereas expression of Gli1 and PTCH1 is observed both in the cancer and in the surrounding stroma.
  • Treatment of gastric cancer cells with KAAD-cyclopamine, a hedgehog signaling inhibitor, decreases expression of Gli1 and PTCH1, resulting in cell growth inhibition and apoptosis.
  • Thus, our analysis of in vivo tissues indicates that the hedgehog pathway is frequently activated in advanced gastric adenocarcinomas; our in vitro studies suggest that hedgehog signaling contributes to gastric cancer cell growth.
  • These data predict that targeted inhibition of the hedgehog pathway may be effective in the prevention and treatment of advanced gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905200.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


43. Pinto RP, Lima FK, Kulkzynski JM, Moreira LF: Expression of P16 and PDGFR-beta in gastric adenocarcinoma. Rev Col Bras Cir; 2009 Jul;36(3):199-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P16 and PDGFR-beta in gastric adenocarcinoma.
  • OBJECTIVES: To detect immunohistochemistry expression of p16 and PDGFR-beta on gastric adenocarcinoma.
  • METHODS: Thirty six patients submitted to surgery for gastric adenocarcinoma between 1998 and 2002 at Santa Casa de Porto Alegre Hospital have been studied.
  • [MeSH-major] Adenocarcinoma / metabolism. Neoplasm Proteins / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076898.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


44. Huang Y, Zhu Z, Sun M, Wang J, Guo R, Shen L, Wu W: Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells. Cancer Biol Ther; 2010 Jun 15;9(12):1000-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells.
  • AIMS: The aim of this study was to investigate whether AQP3 expression in the human gastric carcinoma cell lines, AGS and SGC7901, enhances cell migration and proliferation.
  • RESULTS: Here, we showed that AQP3 is expressed in the human gastric cancer cell lines, AGS and SGC7901.
  • The hEGF induced AQP3 expression in a time- and dose-dependent manner and increased gastric cancer cell migration and proliferation.
  • CONCLUSIONS: Collectively, our findings provide for the first time that AQP3 plays a critical role in hEGF-induced cancer cell migration and proliferation and that hEGF induces AQP3 expression via ERK signal transduction pathways.
  • These finds provide evidence for a novel role of AQP3 in human gastric carcinoma as a potentially important determinant of tumor growth and spread.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aquaporin 3 / metabolism. Epidermal Growth Factor / physiology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364107.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 158801-98-0 / Aquaporin 3; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


45. Rubiales AS, Ovelar Y, Beltrán de Heredia J, del Valle ML: [Synchronous diagnosis of gastric adenocarcinoma and GIST]. An Med Interna; 2005 Dec;22(12):606-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous diagnosis of gastric adenocarcinoma and GIST].
  • [Transliterated title] Diagnóstico simultáneo de adenocarcinoma y GIST gástricos.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523554.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


46. Takahashi T, Kochi M, Kanamori N, Kaiga T, Funada T, Fujii M, Takayama T: [Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1885-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case].
  • The patient was a 51-year-old male diagnosed with gastric cancer in July 1999 by endoscopic examination, revealing multiple liver metastasis with abdominal computed tomography (CT).
  • The serum levels of alpha-fetoprotein (AFP)were determined to be 91 ng/mL, and tumors were histopathologically identified as AFP-producing gastric cancer by immunohistological staining.
  • The primary gastric tumor became a ulcer, and disappearance of the cancer was confirmed histologically.
  • In April 2000, there was no sign of the liver metastases, but endoscopic examination showed IIc-like lesion in the stomach.
  • The pathological diagnosis was por 1, ss, ly2, v1, n(1+).
  • We experienced this AFP-producing gastric cancer in which CR was possible by FLEP.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920393.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / alpha-Fetoproteins; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


47. Kim YG, Jang BI, Kim TN: A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection. Gut Liver; 2010 Mar;4(1):25-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We reviewed the medical records of patients who underwent endoscopic submucosal dissection (ESD) for gastric neoplasia at Yeungnam University Hospital between January 2008 and May 2009.
  • In the revaprazan group, only one patient had stage H2 disease: a 54-year-old man with a 5.5-cm lesion after ESD of the ulcer, type IIa early gastric cancer, and adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1992 May;33(5):617-21 [1319381.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jul;326(1):163-70 [18411413.001]
  • [Cites] Gastroenterology. 1992 Aug;103(2):407-13 [1634059.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):695-8 [1732139.001]
  • [Cites] Dig Dis Sci. 1988 May;33(5):619-24 [3282850.001]
  • [Cites] Biochem Pharmacol. 1995 Nov 9;50(10):1543-9 [7503755.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:277-305 [7598495.001]
  • [Cites] Dig Dis Sci. 1996 Oct;41(10):2039-47 [8888719.001]
  • [Cites] Free Radic Biol Med. 1996;21(5):727-31 [8891677.001]
  • [Cites] Pharmacotherapy. 1997 Jan-Feb;17(1):22-37 [9017763.001]
  • [Cites] J Clin Biochem Nutr. 2008 May;42(3):191-6 [18545640.001]
  • [Cites] Dig Dis Sci. 2009 Jul;54(7):1494-9 [19005762.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1130-4 [19337238.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:74-81 [10807407.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1502-11 [11705756.001]
  • [Cites] J Clin Pharmacol. 2004 Jan;44(1):73-82 [14681344.001]
  • [Cites] Wound Repair Regen. 2004 Jan-Feb;12(1):93-9 [14974970.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):213-7 [15278047.001]
  • [Cites] Hum Mol Genet. 2004 Nov 15;13(22):2813-21 [15385447.001]
  • [Cites] Chin J Dig Dis. 2005;6(3):119-21 [16045601.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):685-9 [16082584.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23740-7 [16754665.001]
  • [Cites] J Med Invest. 2007 Feb;54(1-2):83-90 [17380018.001]
  • [Cites] Am J Physiol. 1992 Jun;262(6 Pt 2):H1955-8 [1320341.001]
  • (PMID = 20479909.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871596
  • [Keywords] NOTNLM ; Acid pump antagonists / Endoscopic submucosal dissection / Proton pump inhibitors / Rabeprazole / Revaprazan
  •  go-up   go-down


48. Ringhofer C, Lenglinger J, Izay B, Kolarik K, Zacherl J, Eisler M, Wrba F, Chandrasoma PT, Cosentini EP, Prager G, Riegler M: Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr; 2008;120(11-12):350-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Discrepancy exists between the endoscopic (rugal folds) and the histopathologic (oxyntic mucosa) definition of proximal stomach.
  • [MeSH-major] Endoscopy, Digestive System. Esophagogastric Junction / pathology. Gastroesophageal Reflux / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Biopsy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Female. Gastric Mucosa / pathology. Hernia, Hiatal / diagnosis. Hernia, Hiatal / pathology. Humans. Male. Metaplasia. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(13-14):405-11 [17671821.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1162-5 [17531009.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):11-21 [17592284.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1207-12 [12218577.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1392-9 [17101315.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1611-6 [16863568.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):150-3 [17591489.001]
  • [Cites] Gut. 1997 Nov;41(5):585-9 [9414961.001]
  • [Cites] Gut. 2003 Jun;52(6):791-6 [12740332.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):706-10 [17460453.001]
  • [Cites] Arch Pathol Lab Med. 2005 Feb;129(2):164-9 [15679412.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):654-61 [16933002.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):212-7 [15046207.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1416-20 [16863541.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):522-30; discussion 530-2 [9351720.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1853-67 [16144130.001]
  • [Cites] Gut. 1993 Jan;34(1):21-7 [8432446.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):470-1 [17609649.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):960-8 [12826888.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):402-9 [10716154.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Scand J Gastroenterol. 1999 Nov;34(11):1065-70 [10582754.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1188-93 [11688579.001]
  • [Cites] Surg Endosc. 1999 Dec;13(12):1184-8 [10594262.001]
  • [Cites] Dis Esophagus. 1998 Apr;11(2):101-5 [9779365.001]
  • [Cites] Gut. 2003 Dec;52(12):1798; author reply 1798-9 [14633968.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):190-200 [15654800.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):235-8 [16391958.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep;24 Suppl 2:17-26 [16939429.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):929-36 [12826885.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2178-82 [17436103.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):302-11 [11866266.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S33-41 [15758657.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):920-4 [15309878.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Scand J Gastroenterol. 2005 Aug;40(8):893-902 [16165707.001]
  • [Cites] Dis Esophagus. 2003;16(1):24-8 [12581250.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(9-10):283-90 [17571232.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):619-26 [11685024.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):40-7 [16360414.001]
  • [Cites] Gut. 2004 Oct;53(10):1402-7 [15361485.001]
  • (PMID = 18709523.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


49. Chae YS, Kim JG, Sohn SK, Cho YY, Moon JH, Bae HI, Park JY, Lee MH, Lee HC, Chung HY, Yu W: Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology; 2006;71(3-4):266-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer.
  • This study evaluates the potential association of three VEGF gene polymorphisms (-460T > C, +405G > C, and 936C > T) with the susceptibility to and clinicopathologic characteristics of gastric cancer.
  • However, for the +405G > C polymorphism, the +405C allele was associated with a significantly decreased susceptibility to gastric cancer [odds ratio (OR) 0.686; 95% confidence interval (CI) 0.564-0.834].
  • Although there was no significant difference in the distribution of the 936C > T polymorphism between the two groups, the 936T allele was associated with a decreased susceptibility to gastric cancer (OR 0.757; 95% CI 0.591-0.970).
  • In the haplotype analyses, the haplotype TCT (OR 0.405; 95% CI 0.263-0.624) was most closely associated with a decreased susceptibility to gastric cancer.
  • However, no significant association was observed between the frequency of the genotypes or alleles and the clinicopathologic characteristics of gastric cancer.
  • CONCLUSION: These observations imply that the VEGF gene polymorphisms may be associated with the susceptibility to gastric cancer.
  • However, further studies of other VEGF sequence variants and their biological functions are needed to understand the role of the VEGF polymorphisms in determining the susceptibility to gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671399.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


50. Blanke CD, Chansky K, Christman KL, Hundahl SA, Issell BF, Van Veldhuizen PJ Jr, Budd GT, Abbruzzese JL, Macdonald JS: S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. Am J Clin Oncol; 2010 Apr;33(2):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
  • OBJECTIVE: The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting.
  • METHODS: Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression.
  • Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion.
  • CONCLUSIONS: This regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. TRIMETREXATE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 May;58(4):273-9 [10838491.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):729-33 [18083691.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):87-91 [11863117.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):92-4 [11865815.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Cancer Res. 1982 May;42(5):1696-702 [6461409.001]
  • [Cites] Biochem Pharmacol. 1984 May 15;33(10):1697-9 [6233981.001]
  • [Cites] NCI Monogr. 1987;(5):105-9 [2963228.001]
  • [Cites] NCI Monogr. 1987;(5):99-104 [2963231.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):5029-35 [2970294.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):124-30 [2909752.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Jun;25(6):977-82 [2526736.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(5):314-20 [2758561.001]
  • [Cites] Cancer Res. 1989 Oct 15;49(20):5586-90 [2477146.001]
  • [Cites] Anticancer Res. 1989 Jul-Aug;9(4):1025-6 [2817784.001]
  • [Cites] Invest New Drugs. 1990 May;8(2):159-66 [2143500.001]
  • [Cites] J Natl Cancer Inst. 1992 Jul 1;84(13):1033-8 [1376779.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):695-700 [7512128.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):915-20 [9060528.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):4001-3 [11099333.001]
  • (PMID = 19770625.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46136; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA032102-32; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA52757; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; UPN4ITI8T4 / Trimetrexate
  • [Other-IDs] NLM/ NIHMS244743; NLM/ PMC2967385
  •  go-up   go-down


51. Liu YJ, Yang Z, Hao LS, Xia L, Jia QB, Wu XT: Synchronous incidental gastrointestinal stromal and epithelial malignant tumors. World J Gastroenterol; 2009 Apr 28;15(16):2027-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From January 1, 2000 to December 31, 2007, 13804 cases of gastrointestinal epithelial malignant tumor (EMT) and 521 cases of pancreatic adenocarcinoma (PAC) were successfully treated with surgery at the Department of General Surgery and the Department of Thoracic Surgery, West China Hospital, Sichuan University, China.
  • Of these tumors, 27 were found in 1.13% patients with esophageal squamous cell carcinoma (ESCC), 22 in 0.53% patients with gastric adenocarcinoma (GAC), 2 in 0.38% patients with PAC, 2 in 0.03% patients with colorectal adenocarcinoma, and 1 in one patient with GAC accompanying ESCC, respectively.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1629-35 [18059218.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):255-6 [11846308.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6 [12167128.001]
  • [Cites] J Clin Gastroenterol. 2002 Oct;35(4):332-4 [12352297.001]
  • [Cites] J Gastroenterol. 2002;37(11):947-53 [12483251.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Dec;21(4):617-20 [12636111.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1417-8 [12663737.001]
  • [Cites] Intern Med. 2004 Feb;43(2):102-5 [15005250.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):LE13-4 [15278004.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1118-9 [15452175.001]
  • [Cites] Digestion. 1999 Jul-Aug;60(4):363-6 [10394032.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):49-53 [15692952.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jun;20(6):818-24 [15946127.001]
  • [Cites] Z Gastroenterol. 2005 Sep;43(9):1025-30 [16142610.001]
  • [Cites] Obes Surg. 2005 Nov-Dec;15(10):1384-8 [16354516.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):815-7 [16521203.001]
  • [Cites] Rev Esp Enferm Dig. 2006 May;98(5):387-9 [16944999.001]
  • [Cites] World J Gastroenterol. 2006 Sep 7;12(33):5360-2 [16981268.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Hum Pathol. 2006 Dec;37(12):1527-35 [16996566.001]
  • [Cites] Surg Today. 2007;37(1):74-7 [17186352.001]
  • [Cites] Gastroenterol Hepatol. 2007 Nov;30(9):534-7 [17980131.001]
  • [Cites] Ann Thorac Surg. 2000 Aug;70(2):660-2 [10969699.001]
  • (PMID = 19399938.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2675096
  •  go-up   go-down


52. Athanassiou E, Vamvakopoulou DN, Zacharoulis D, Paroutoglou G, Sioutopoulou D, Tepetes K, Nomikos I, Vamvakopoulos NC: Immunophenotypic evaluation of DNA mismatch repair markers in 2 cases of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel. Appl Immunohistochem Mol Morphol; 2010 May;18(3):288-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic evaluation of DNA mismatch repair markers in 2 cases of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel.
  • OBJECTIVES: To assess the prognostic value of combined mismatch DNA repair (MMR) phenotyping in 2 synchronous histomorphologically distinct gastric adenocarcinomas (GADCs), each accompanied by gastrointestinal stromal tumors (GISTs) of the proximal small bowel.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090515.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


53. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10.
  • Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


54. Jones GE, Strauss DC, Forshaw MJ, Deere H, Mahedeva U, Mason RC: Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature. World J Surg Oncol; 2007;5:75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature.
  • BACKGROUND: The stomach is an infrequent site of breast cancer metastasis.
  • It may prove very difficult to distinguish a breast cancer metastasis to the stomach from a primary gastric cancer on the basis of clinical, endoscopic, radiological and histopathological features.
  • It is important to make this distinction as the basis of treatment for breast cancer metastasis to the stomach is usually with systemic therapies rather than surgery.
  • CASE PRESENTATIONS: The first patient, a 51 year old woman, developed an apparently localised signet-ring gastric adenocarcinoma 3 years after treatment for lobular breast cancer with no clinical evidence of recurrence.
  • Initial gastric biopsies were negative for both oestrogen and progesterone receptors.
  • Immunohistochemistry for Gross Cystic Disease Fluid Protein was positive, suggesting metastatic breast cancer.
  • The second patient, a 61 year old woman, developed a proximal gastric signet-ring adenocarcinoma 14 years after initial treatment for breast cancer which had subsequently recurred with bony and pleural metastases.
  • In this case, initial gastric biopsies were positive for both oestrogen and progesterone receptors; subsequent investigations revealed widespread metastases and surgery was avoided.
  • CONCLUSION: In patients with a history of breast cancer, a high index of suspicion for potential breast cancer metastasis to the stomach should be maintained when new gastrointestinal symptoms develop or an apparent primary gastric cancer is diagnosed.
  • Complete histopathological and immunohistochemical analysis of the gastric biopsies and comparison with the original breast cancer pathology is important.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / secondary. Stomach Neoplasms / diagnosis. Stomach Neoplasms / secondary
  • [MeSH-minor] Carcinoma, Signet Ring Cell / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2004 Jun;36(6):543-50 [15202052.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Sep;31(3):701-13 [12481726.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Biol Chem. 1973 Aug 25;248(16):5736-41 [4723913.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10):903-13 [1190198.001]
  • [Cites] Ann Surg. 1977 Mar;185(3):279-85 [843124.001]
  • [Cites] Mayo Clin Proc. 1980 Dec;55(12):747-53 [6261047.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Hum Pathol. 1989 Mar;20(3):281-7 [2542151.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):130-5 [1568608.001]
  • [Cites] Surg Today. 1992;22(5):421-5 [1421863.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):103-4 [8267696.001]
  • [Cites] Mod Pathol. 1993 Sep;6(5):516-20 [8248106.001]
  • [Cites] J Korean Med Sci. 1997 Jun;12(3):256-61 [9250925.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Endoscopy. 1998 Nov;30(9):800-4 [9932762.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1561-73 [15537965.001]
  • [Cites] Histopathology. 2005 Feb;46(2):153-7 [15693887.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):338-47 [15737028.001]
  • [Cites] Onkologie. 2005 May;28(5):270-2 [15867484.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):886-94 [16177864.001]
  • [Cites] Rev Gastroenterol Disord. 2006 Winter;6(1):1-12 [16520707.001]
  • [Cites] APMIS. 2006 Oct;114(10):712-9 [17004974.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7326-8 [17143949.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Lancet Oncol. 2007 Jan;8(1):55-62 [17196511.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):795-800 [10954469.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2214-21 [11147591.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • [Cites] J Gastrointest Surg. 2002 Jul-Aug;6(4):614-6 [12127129.001]
  • [Cites] Am J Dig Dis. 1968 Oct;13(10):868-73 [5303029.001]
  • (PMID = 17620117.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1937002
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


55. Mesa H, Rawal A, Rezcallah A, Iwamoto C, Niehans GA, Druck P, Gupta P: "Burned out" testicular seminoma presenting as a primary gastric malignancy. Int J Clin Oncol; 2009 Feb;14(1):74-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Burned out" testicular seminoma presenting as a primary gastric malignancy.
  • In contrast to primary gastric adenocarcinomas, germ cell tumors are potentially curable even when metastatic.
  • Here we report on a 55-year-old man who presented with clinical and endoscopic features indicative of a primary gastric carcinoma.
  • This case describes the radiological and pathological features that helped differentiate this rare situation from the much more common gastric adenocarcinoma, and extends the diagnostic possibilities that must be considered in patients presenting with gastric ulcers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasms, Unknown Primary. Seminoma / secondary. Stomach Neoplasms / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Gastrectomy. Gastroscopy. Humans. Ifosfamide / administration & dosage. Immunohistochemistry. Male. Middle Aged. Orchiectomy. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Apr 15;97(8):1869-75 [12673712.001]
  • [Cites] Histopathology. 2006 Sep;49(3):290-7 [16918976.001]
  • [Cites] JAMA. 1974 Aug 12;229(7):825-6 [4407823.001]
  • [Cites] Prog Urol. 1996 Apr;6(2):278-81 [8777424.001]
  • [Cites] Schweiz Med Wochenschr. 1999 Feb 13;129(6):235-40 [10093882.001]
  • [Cites] Actas Urol Esp. 1999 Nov-Dec;23(10):880-4 [10670132.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1596-600 [2311070.001]
  • [Cites] J Clin Gastroenterol. 1981;3 Suppl 1:35-7 [7328295.001]
  • [Cites] Br J Radiol. 2004 Dec;77(924):1000-6 [15569641.001]
  • [Cites] Acta Chir Scand. 1972;138(7):739-42 [4642714.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):63-70 [12491506.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1412-8 [12954581.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] J Ultrasound Med. 2003 May;22(5):515-21 [12751863.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Dec 29;377(1):67-78 [146949.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):353-8 [9640221.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1974;363(2):97-112 [4852993.001]
  • [Cites] Int J Urol. 2005 Jan;12(1):115-6 [15661068.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):191-4 [1582512.001]
  • [Cites] Clin Transl Oncol. 2005 Nov;7(10):458-63 [16373055.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):121-4 [11863093.001]
  • [Cites] Clin Radiol. 1987 Jan;38(1):63-5 [3816068.001]
  • [Cites] Orv Hetil. 1985 Sep 29;126(39):2409-10 [4047643.001]
  • [Cites] Ann Oncol. 1992 Apr;3(4):283-9 [1327076.001]
  • [Cites] BJU Int. 2004 Jul;94(1):74-8 [15217435.001]
  • (PMID = 19225929.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; ICE protocol 1
  •  go-up   go-down


56. Jovanović I, Alempijević T, Milosavljević T, Popović D, Bjelović M, Micev M, Pesko P: [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients]. Srp Arh Celok Lek; 2009 May-Jun;137(5-6):249-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients].
  • INTRODUCTION In the past two decades, the increased frequency of distal esophageal adenocarcinoma, esophagogastric junction and proximal gastric adenocarcinoma has been observed.
  • The vast majority of these tumours are diagnosed in advanced stages, when the prognosis is poorer than in other gastric cancers.
  • OBJECTIVE: The aim of our study was to analyze the demographic and clinicopathological characteristics of patients operated on for Barrett's, cardia and distal gastric adenocarcinomas, as well as to study the influence of manifestations of each cancerogenetic indication on the studied clinicopathological parameters and to analyze the 5-year survival rate of patients surgically treated for cardia adenocarcinoma in relation to the patients operated on for distal gastric adenocarcinoma.
  • In the patients operated on for Barrett's and cardia cancers, the tumours invaded more deeply the wall layers, i.e. they were significantly more invasive than the distal gastric tumour.
  • The lymph node involvement was present in 87.5% of patients with Barrett's cancer, in 80% with cardia cancer and in 87% with distal gastric cancer.
  • The 3-year survival rate of patients operated on for cardia cancer was 47.4% and the 5-year survival rate was 31.6%, while the 3-year survival rate of patients operated on for distal gastric cancer was 46.2% and the 5-year survival rate was 34.6%.
  • Singly, the patients' gender, cancer type and the degree of tumour differentiation had no influence on the length of patients' postsurgical survival rate.
  • CONCLUSION: At the time of diagnosis cardia cancer and cancers developed at the location of the Barrett's oesophagus, developed significant deeper per continuitatem than gastric cancer.
  • There were no other differences in regard to the analyzed clinicopathological parameters among the tumours of these three locations, and there was no difference between the 3-year and 5-year survival rate between the patients operated on for gastric cancer and cardia cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / complications. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594065.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


57. Jørgensen JT: Targeted HER2 treatment in advanced gastric cancer. Oncology; 2010;78(1):26-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted HER2 treatment in advanced gastric cancer.
  • Amplification of the HER2 gene and over-expression of the HER2 protein in gastric cancer have been shown in a large number of studies.
  • Preclinical in vitro and in vivo studies have demonstrated that both trastuzumab and lapatinib are effective in different gastric cancer models and have thus lead to the initiation of clinical studies.
  • In the first phase III study, the ToGA trial, HER2-positive patients with advanced gastroesophageal and gastric adenocarcinoma were randomized to receive 5-fluorouracil/capecitabine and cisplatin either alone or in combination with trastuzumab.
  • It is expected that the encouraging results from the ToGA trial will have an immediate impact on the management of patients and that routine HER2 testing of patients with advanced gastric cancer will be initiated within a relatively short period of time.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Genes, erbB-2 / genetics. Receptor, ErbB-2 / biosynthesis. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20185938.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 0VUA21238F / lapatinib; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Vasudevan B: An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity? Indian J Pharmacol; 2010 Oct;42(5):326-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 59-year-old man with adenocarcinoma of stomach was prescribed capecitabine as adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Nurs Forum. 1999 May;26(4):753-62 [10337653.001]
  • [Cites] J Cutan Pathol. 1999 Jul;26(6):287-94 [10472757.001]
  • [Cites] Cancer Invest. 2002;20(1):3-10 [11853000.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):566-75 [12056707.001]
  • [Cites] Cutan Ocul Toxicol. 2008;27(4):311-5 [19037763.001]
  • [Cites] Ann Intern Med. 1984 Dec;101(6):798-9 [6497196.001]
  • [Cites] Cutis. 2004 Feb;73(2):101-6 [15027515.001]
  • [Cites] Clin Ther. 2005 Jan;27(1):23-44 [15763604.001]
  • [Cites] Korean J Intern Med. 2007 Jun;22(2):109-12 [17616027.001]
  • [Cites] Indian J Dermatol. 2008 Jan;53(1):43-4 [19967024.001]
  • (PMID = 21206630.001).
  • [ISSN] 1998-3751
  • [Journal-full-title] Indian journal of pharmacology
  • [ISO-abbreviation] Indian J Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2959221
  • [Keywords] NOTNLM ; Capecitabine / hand-foot syndrome / hyperpigmentation
  •  go-up   go-down


59. Moretó M: Diagnosis of esophagogastric tumors. Endoscopy; 2005 Jan;37(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of esophagogastric tumors.
  • 1) The place of endoscopic ultrasonography (EUS) as the best locoregional staging technique for cancer of the esophagus has been further consolidated.
  • 4) The incidence of hypopharyngeal cancer increases after resection for esophageal carcinoma.
  • With regard to gastric tumors, 1) Helicobacter pylori eradication can significantly reduce the development of gastric cancer, but only in patients without precancerous lesions.
  • 4) In patients who have undergone esophagectomy for esophageal cancer, annual follow-up endoscopies are vital for detecting early secondary gastric cancer and ulcerations in which curative treatment is possible.
  • 5) High-resolution endoscopy allows more precise diagnosis of early gastric cancer.
  • The presence of irregular minute vessels and variations in vessel caliber were found to be specific of early gastric cancer.
  • 6) Infrared-ray electronic endoscopy combined with indocyanine green injection appears to be effective in detecting sentinel nodes that contain metastases in patients with gastric cancer.
  • 7) Gastric adenocarcinoma was found to show specific changes in the fluorescence spectra emitted, in comparison with normal gastric mucosa.
  • However, there was wide variation in the emitted autofluorescence spectra in gastric cancer with signet-ring cells in comparison with normal mucosa.
  • [MeSH-major] Endoscopy, Digestive System. Esophageal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15657854.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


60. Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagström J, Haglund C: MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol; 2010 Jun;31(3):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MMP-7 overexpression is an independent prognostic marker in gastric cancer.
  • To enable cancer to invade and to metastasize, the surrounding stroma must be degraded.
  • The purpose of this study was to evaluate the association between MMP-7 tissue expression and patients' prognosis in gastric cancer.
  • From 264 patients who underwent surgery for gastric cancer, surgical specimens were collected on tissue array blocks and stained by immunohistochemistry for MMP-7.
  • In conclusion, our results suggest that MMP-7 expression may prove helpful in evaluating gastric cancer prognosis.
  • [MeSH-major] Matrix Metalloproteinase 7 / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Aged. Female. Humans. Male. Multivariate Analysis. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 1991;117(2):144-50 [1848860.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1113-20 [16474169.001]
  • [Cites] Int J Oncol. 1998 Nov;13(5):1031-5 [9772296.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1290-6 [9098015.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):491-7 [16615152.001]
  • [Cites] J Gastroenterol. 2004;39(5):434-40 [15175941.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1118-27 [11181677.001]
  • [Cites] J Clin Invest. 2002 Jun;109(11):1437-44 [12045257.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 1991 Jun 19;48(4):550-6 [1646178.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):823-30 [16969501.001]
  • [Cites] Gut. 1999 Aug;45(2):252-8 [10403738.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):269-85 [14619979.001]
  • [Cites] Mol Carcinog. 1991;4(6):527-33 [1793490.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):187-94 [9583735.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jan;231(1):20-7 [16380641.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):699-704 [1701851.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):341-5 [9344615.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7362-8 [16243808.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):351-62 [8821095.001]
  • [Cites] Gut. 1996 Sep;39(3):444-8 [8949652.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):1-21 [8814982.001]
  • [Cites] Chem Biol. 1996 Nov;3(11):895-904 [8939708.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):27-39 [15621988.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8243-9 [15623600.001]
  • (PMID = 20300917.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


61. Ali N, Kamran N, Adil S, Pervez S: Metastatic signet ring gastric adenocarcinoma presenting with microangiopathic hemolytic anemia. Indian J Gastroenterol; 2007 Jul-Aug;26(4):185-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic signet ring gastric adenocarcinoma presenting with microangiopathic hemolytic anemia.
  • Metastatic adenocarcinoma presenting as microangiopathic hemolytic anemia (MAHA) and leukoerythroblastic blood picture is rare.
  • We report three patients who presented with MAHA as the initial symptom of metastatic signet ring cell gastric adenocarcinoma.
  • One patient had past history of gastric ulcer.
  • In all these patients the initial diagnosis was based on peripheral blood smear followed by bone marrow biopsy; upper GI endoscopy showed presence of gastric ulcers with focally scattered neo-plastic signet ring cells on histopathology.
  • All patients died within a week of diagnosis.
  • [MeSH-major] Anemia, Hemolytic / etiology. Bone Marrow Neoplasms / secondary. Carcinoma, Signet Ring Cell / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986749.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


62. Reynolds JV, Ravi N, Muldoon C, Larkin JO, Rowley S, O'Byrne K, Hollywood D, O'Toole D: Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg; 2010 Dec;34(12):2821-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.
  • BACKGROUND: Adenocarcinoma of the esophagogastric junction (AEG) as described by Siewert et al. is classified as one entity in the latest (7th Edition) American Joint Cancer Committee/International Union Against Cancer (AJCC/UICC) manual, compared with the previous mix of esophageal and gastric staging systems.
  • The origin of AEG tumors, esophageal or gastric, and their biology remain controversial, particularly for AEG type II (cardia) tumors.
  • This may reflect earlier diagnosis, but an alternative possibility, that type I may be a unique paradigm with more favorable biology, requires further study.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Jun;35(6):1409-10; author reply 1411 [21301836.001]
  • [Cites] Ann Surg. 2009 Nov;250(5):729-37 [19801928.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:55-60; discussion 61-2 [15456465.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):569-75 [17414104.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Sep;138(3):594-602; discussion 601-2 [19698841.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] World J Surg Oncol. 2006 Nov 21;4:82 [17118194.001]
  • [Cites] Ann Surg. 2007 May;245(5):707-16 [17457163.001]
  • [Cites] Oncology. 2010;78(1):26-33 [20185938.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Ann Oncol. 2009 May;20(5):885-91 [19164454.001]
  • [Cites] Ann Thorac Surg. 2007 May;83(5):1814-9 [17462405.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4 Suppl):S49-53 [17916519.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):365-71 [18216546.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Br J Surg. 2005 Jan;92(1):60-7 [15584066.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):549-56 [18936567.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):40-7 [16360414.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 20827475.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Hotta K, Oyama T, Akamatsu T, Tomori A, Hasebe O, Nakamura N, Kojima E, Suga T, Miyabayashi H, Ohta H: A comparison of outcomes of endoscopic submucosal dissection (ESD) For early gastric neoplasms between high-volume and low-volume centers: multi-center retrospective questionnaire study conducted by the Nagano ESD Study Group. Intern Med; 2010;49(4):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of outcomes of endoscopic submucosal dissection (ESD) For early gastric neoplasms between high-volume and low-volume centers: multi-center retrospective questionnaire study conducted by the Nagano ESD Study Group.
  • OBJECTIVE: Outcomes of endoscopic submucosal dissection (ESD) for early gastric neoplasms at low-volume centers have been unknown, because all previous reports have studied in advanced single centers.
  • Early gastric cancer (EGC) was divided into three categories on the basis of pathological diagnosis-standard indication (SI), expanded indication (EI) and out-of-indication (OI).
  • RESULTS: A total of 703 early gastric neoplasms (586 EGCs, 117 gastric adenomas) were treated with ESD from January to December 2005.
  • CONCLUSION: There were no significant difference in the outcomes of ESD for early gastric neoplasms between high- and low volume centers.
  • [MeSH-major] Endoscopy, Gastrointestinal. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Dissection. Gastric Mucosa / surgery. Humans. Japan. Postoperative Complications / etiology. Retrospective Studies. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med. 2010;49(4):251-2 [20154427.001]
  • (PMID = 20154428.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


64. Richards DA, Boehm KA, Anthony SP: Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs; 2007 Jul;16(7):1059-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
  • Gastric cancer is a major worldwide problem and is a leading cause of death.
  • The incidence of distal gastric cancer is declining; however, there has been a rapid rise in the incidence of adenocarcinoma of the gastroesophageal junction, which is a more aggressive entity.
  • This review examines recent advances in the treatment of gastroesophageal junction adenocarcinoma and gastric cancer, newer agents and the potential agents that are in development, which can be logically applied to the treatment of this devastating disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594189.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 56
  •  go-up   go-down


65. Ebert S, Pilgram SM, Bähr M, Kermer P: Bilateral ophthalmoplegia due to symmetric cavernous sinus metastasis from gastric adenocarcinoma. J Neurol Sci; 2009 Apr 15;279(1-2):106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ophthalmoplegia due to symmetric cavernous sinus metastasis from gastric adenocarcinoma.
  • We report a patient with rapidly progressive bilateral total ophthalmoplegia due to bilateral cavernous sinus metastasis from gastric adenocarcinoma.
  • Our patient impressively demonstrates the relevance of this differential diagnosis of bilateral ophthalmoplegia.
  • Repeated CCTs and cMRIs were required to find the diagnosis and finally start a therapy, demonstrating that even with advanced neuroradiological techniques, repetition of imaging within short intervals can be necessary to detect rapidly developing metastatic infiltrations as early as possible.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / complications. Brain Neoplasms / secondary. Cavernous Sinus. Ophthalmoplegia / etiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187943.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Ward MH, Heineman EF, Markin RS, Weisenburger DD: Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite. Int J Occup Environ Health; 2008 Jul-Sep;14(3):193-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite.
  • We conducted a population-based case-control study of adenocarcinoma of the stomach and esophagus in Nebraska, U.S.A.
  • Among those who primarily used public water supplies (79 distal stomach, 84 esophagus, 321 controls), average nitrate levels were not associated with risk (highest versus lowest quartile: stomach OR=1.2, 95% CI [0.5-2.7]; esophagus OR=1.3, 95% CI [0.6-3.1]).
  • We observed the highest ORs for distal stomach cancer among those with higher water nitrate ingestion and higher intake of processed meat compared with low intakes of both; however, the test for positive interaction was not significant (p=0.213).
  • We did not observe this pattern for esophagus cancer.
  • Increasing intake of nitrate and nitrite from animal sources was associated with elevated ORs for stomach cancer and with a significant positive trend in risk of esophagus cancer (P-trend=0.325 and 0.015, respectively).
  • [MeSH-major] Adenocarcinoma / epidemiology. Diet / adverse effects. Esophageal Neoplasms / epidemiology. Nitrates / analysis. Nitrites / analysis. Stomach Neoplasms / epidemiology. Water Supply / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):163-72 [11246845.001]
  • [Cites] Nutr Cancer. 2007;59(2):185-91 [18001213.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3522S-3525S [12421881.001]
  • [Cites] Cancer Res. 1989 Jun 1;49(11):3117-21 [2720669.001]
  • [Cites] Epidemiology. 1990 Sep;1(5):349-56 [2078610.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):58-64 [2081241.001]
  • [Cites] Arch Environ Health. 1992 Jul-Aug;47(4):292-4 [1497383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):455-61 [1302557.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):29-36 [7894321.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):14-9 [9096659.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):129-35 [9662263.001]
  • [Cites] Environ Health Perspect. 1998 Aug;106(8):459-63 [9681972.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):852-6 [10074917.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1607-14 [16263519.001]
  • [Cites] J Occup Environ Med. 2005 Dec;47(12):1260-7 [16340707.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1497-501 [16571648.001]
  • [Cites] World J Gastroenterol. 2006 Jul 21;12(27):4296-303 [16865769.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):628-9 [16900606.001]
  • [Cites] Environ Sci Technol. 2006 Dec 15;40(24):7834-40 [17256535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • (PMID = 18686719.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010125-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrates; 0 / Nitrites; 0 / Water Pollutants, Chemical
  • [Other-IDs] NLM/ NIHMS162722; NLM/ PMC2797489
  •  go-up   go-down


67. Chen J, Lou J, Liu T, Wu R, Dong X, He Q, Yang B, Hu Y: Synthesis and in-vitro antitumor activities of some mannich bases of 9-alkyl-1,2,3,4-tetrahydrocarbazole-1-ones. Arch Pharm (Weinheim); 2009 Mar;342(3):165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the compounds were tested for their cytotoxic activity in vitro against four human tumor cell lines including human non-small lung cancer cells (A549), human gastric adenocarcinoma (SGC), human colon cancer cell (HCT116), human myeoloid leukemia cells (K562), and one multi-drug resistant subline (KB-VCR).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212985.001).
  • [ISSN] 1521-4184
  • [Journal-full-title] Archiv der Pharmazie
  • [ISO-abbreviation] Arch. Pharm. (Weinheim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbazoles; 0 / Mannich Bases; 942-01-8 / 1,2,3,4-tetrahydrocarbazole
  •  go-up   go-down


68. D'Elios MM, Andersen LP: Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter; 2009 Sep;14 Suppl 1:21-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori infects almost half of the population worldwide and represents the major cause of gastroduodenal diseases, such as duodenal and gastric ulcer, gastric adenocarcinoma, autoimmune gastritis, and B-cell lymphoma of mucosa-associated lymphoid tissue.
  • Helicobacter pylori induces the activation of a complex and fascinating cytokine and chemokine network in the gastric mucosa.
  • During the last year, significant progress was made on the road to the first efficient vaccine for H. pylori that will represent a novel and very important bullet against both infection and gastric cancer.
  • [MeSH-minor] Animals. Asthma / immunology. Asthma / microbiology. Gastric Mucosa / immunology. Gastric Mucosa / microbiology. Humans. Immunity

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19712164.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Vaccines
  • [Number-of-references] 84
  •  go-up   go-down


69. Liu KT, Chan HM, Lin TJ: An unusual presentation of metastatic gastric adenocarcinoma--acute onset of right neck swelling. J Formos Med Assoc; 2007 Jul;106(7):589-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic gastric adenocarcinoma--acute onset of right neck swelling.
  • Fluid accumulation over deep neck space led to the diagnosis of suspected hemorrhage, and central venous thrombosis was found by computed tomography.
  • Subsequently, gastric adenocarcinoma was confirmed after gastroendoscopy.
  • Gastric adenocarcinoma with distal metastases was finally diagnosed.
  • Malignancy, including gastric adenocarcinoma, is one of the causes that should be considered.

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660150.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


70. Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer; 2010;10:218
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.
  • BACKGROUND: The relationships between the expression of CD133, Ki-67 and prognosis in gastric adenocarcinoma are unknown and needs exploring.
  • METHODS: The samples of gastric adenocarcinoma from 336 Chinese patients with follow-up were analyzed for CD133 and Ki-67 protein expressions by immunohistochemical method.
  • RESULTS: CD133 was expressed in up to 57.4% (193/336) of this group of gastric carcinoma.
  • The expression of CD133 has a positive correlation with that of Ki-67 (r = 0.188, P = 0.001) in gastric adenocarcinoma.
  • CONCLUSIONS: It is suggested that CD133 may play an important role in the evolution of gastric adenocarcinoma and should be considered as a potential marker for the prognosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Glycoproteins / analysis. Ki-67 Antigen / analysis. Peptides / analysis. Stomach Neoplasms / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. China. Female. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Risk Assessment. Time Factors. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jan 1;60(1):18-21 [10646844.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1285-9 [18781171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):414-5 [15004528.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Rocz Akad Med Bialymst. 2004;49 Suppl 1:64-6 [15638377.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):61-4 [17133114.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):687-8 [17151644.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Laryngoscope. 2007 Mar;117(3):455-60 [17334305.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):149-57 [17516028.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):123-9 [18172261.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1389-97 [18349830.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2021-4 [18497883.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):100-9 [18542072.001]
  • [Cites] Int J Clin Pract. 2008 Aug;62(8):1212-8 [18479363.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1578-83 [18754869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:85 [19108713.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):185-93 [19026485.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2258-64 [19437567.001]
  • [Cites] Expert Opin Ther Targets. 2009 Jul;13(7):823-37 [19530986.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):2034-40 [19403300.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] J Transl Med. 2009;7:56 [19583834.001]
  • [Cites] Cancer Treat Rev. 2009 Aug;35(5):403-8 [19369008.001]
  • [Cites] Histopathology. 2009 Sep;55(3):284-93 [19723143.001]
  • [Cites] Cancer Invest. 2009 Oct;27(8):844-50 [19626493.001]
  • [Cites] J Pathol. 2009 Dec;219(4):427-34 [19621338.001]
  • [Cites] Int J Cancer. 2010 Feb 15;126(4):950-8 [19676044.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 20487522.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides
  • [Other-IDs] NLM/ PMC2891633
  •  go-up   go-down


71. Azagra JS, Ibañez-Aguirre JF, Goergen M, Ceuterick M, Bordas-Rivas JM, Almendral-López ML, Moreno-Elola A, Takieddine M, Guérin E: Long-term results of laparoscopic extended surgery in advanced gastric cancer: a series of 101 patients. Hepatogastroenterology; 2006 Mar-Apr;53(68):304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of laparoscopic extended surgery in advanced gastric cancer: a series of 101 patients.
  • BACKGROUND/AIMS: The objective of our paper is to report on the remote results of patients with gastric cancer treated by mini-invasive surgery as a surgical tool with the "intention to treat with laparoscopy".
  • METHODOLOGY: Between June 1993 and January 2004, 101 patients comprising 72 men and 29 women with gastric adenocarcinoma were prospectively selected by two hospitals based on prior agreement (the CHU Charleroi, Belgium, and Zumárraga Hospital, the Basque Country, Spain).
  • Patients with adenocarcinoma of the cardia were excluded.
  • CONCLUSIONS: Laparoscopic gastrectomy with any kind of lymphadenectomy is a heavy but safe operation, and produces acceptable mortality and morbidity rates in patients with advanced gastric cancer in a general poor condition.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy. Laparoscopy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608045.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


72. Cangiano J, Centeno BA, Garrett CR, Cáceres W, de Jesús A, Lee JH, Pavía O, Jove R, Báez L, Sullivan DM, Muro-Cacho CA, Muñoz-Antonia T: Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. Dig Dis Sci; 2008 Aug;53(8):2090-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.
  • Overexpression of the HER2/NEU gene is associated with aggressive behavior and poor prognosis in breast cancer, making the Her2/neu protein a directed-therapy target.
  • Importantly, Her2/neu expression was strong and diffuse in tumors with signet-ring morphology, while other histo-pathological subtypes showed higher intra-tumoral Her2/neu heterogeneity than typically observed in breast cancer.
  • Targeted therapies in gastric cancer directed at EGF-R and Hers-2/neu pathways warrant further investigation.


73. Vang R, Gown AM, Wu LS, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM: Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol; 2006 Nov;19(11):1421-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical studies were performed to compare expression of CDX2 and cytokeratin 20, both markers of intestinal differentiation, in conjunction with coordinate expression of cytokeratin 7, in 90 mucinous tumors involving the ovary: 42 primary ovarian mucinous tumors (31 atypical proliferative (borderline) mucinous tumors (gastrointestinal type), 11 mucinous carcinomas) and 48 metastatic mucinous carcinomas of upper (pancreaticobiliary tract: 14; stomach: five) and lower (colon and rectum: 25; appendix: four) gastrointestinal tract origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Gastrointestinal Neoplasms / chemistry. Homeodomain Proteins / analysis. Keratin-7 / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-20 / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980943.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


74. Kim HO, Hwang SI, Yoo CH, Kim H: Preoperative colonoscopy for patients with gastric adenocarcinoma. J Gastroenterol Hepatol; 2009 Nov;24(11):1740-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative colonoscopy for patients with gastric adenocarcinoma.
  • BACKGROUND AND AIM: In patients with gastric adenocarcinoma (GA), the most common double primary cancer is colorectal cancer.
  • The aim of the present study was to evaluate the necessity of preoperative colonoscopy in patients with GA who have no symptoms of colorectal disease or any past/family history of colorectal cancer.
  • MATERIALS: Colonoscopy was carried out in 205 patients before gastric surgery for treatment of GA.
  • The prevalence of colorectal neoplasms (CRN, adenoma and adenocarcinoma) was evaluated according to age, sex, body mass index (BMI) and stage, location and differentiation of GA.
  • Synchronous adenoma and adenocarcinoma were detected in 68 (33.2%) and four (2.0%) patients, respectively.
  • All of the GA patients with synchronous colorectal adenocarcinoma were older than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colonoscopy. Colorectal Neoplasms / pathology. Gastrectomy. Mass Screening / methods. Neoplasms, Second Primary. Stomach Neoplasms / pathology


75. Xiong ZJ, Lin P, Zhang J, Wang XJ, Wang Q, Ren JJ, Yang HL, Wang J, Wu YY: [Construction of eukaryotic expression plasmid pEGFP-ATP1B1 and its effect on gastric adenocarcinoma cell SGC-7901]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar;39(2):169-72, 176
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction of eukaryotic expression plasmid pEGFP-ATP1B1 and its effect on gastric adenocarcinoma cell SGC-7901].
  • Next pEGFP-ATP1B1 was transferred into gastric adenocarcinoma SGC-7901 cells by lipofectamine, then ATP1B1 mRNA expression in transfected cells was detected by real-time PCR, and also ATPase was detected after cell transfection, as well as the proliferation of such cells was measured by MTT.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Base Sequence. Cell Line, Tumor. Gene Expression. Humans. Microscopy, Fluorescence. Molecular Sequence Data. Plasmids / genetics. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Transfection / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630675.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.3.9 / ATP1B1 protein, human; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


76. Younes M: What is the role of cytokeratins in Barrett/cardia differentiation? Arch Pathol Lab Med; 2005 Feb;129(2):181-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of distinguishing between Barrett metaplasia and intestinal metaplasia of the gastric cardia is now accepted, and the management of each entity is quite different.
  • Patients with Barrett metaplasia are enrolled in surveillance programs, consisting of periodic endoscopy and biopsy, because of the known risk of developing adenocarcinoma of the esophagus.
  • Patients with intestinal metaplasia of the gastric cardia, however, are not currently enrolled in such programs, because this condition carries a low risk of developing adenocarcinoma of the gastric cardia.
  • However, because it may be associated with premalignant lesions elsewhere in the gastric mucosa, we propose that intestinal metaplasia of the gastric cardia may have the same clinical implication as Barrett metaplasia.
  • [MeSH-major] Barrett Esophagus / etiology. Cardia / pathology. Keratins / physiology. Metaplasia / etiology. Stomach Diseases / etiology

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679416.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 68238-35-7 / Keratins
  • [Number-of-references] 16
  •  go-up   go-down


77. Vásquez D, Rodríguez JA, Theoduloz C, Calderon PB, Valderrama JA: Studies on quinones. Part 46. Synthesis and in vitro antitumor evaluation of aminopyrimidoisoquinolinequinones. Eur J Med Chem; 2010 Nov;45(11):5234-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activity of the aminoquinone derivatives was evaluated in vitro using the MTT colorimetric method against one normal cell line (MRC-5 lung fibroblasts) and four human cancer cell lines (AGS human gastric adenocarcinoma; SK-MES-1 human lung cancer cells, and J82 human bladder carcinoma; HL-60 human leukemia) in 72-h drug exposure assays.
  • Among the series, five compounds exhibited interesting antitumor activity against AGS human gastric adenocarcinoma and human lung cancer cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20828890.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinones
  •  go-up   go-down


78. Nakamura M, Motosugi U, Shimizu Y, Kamakura Y, Hasegawa S, Kamada K, Sannohe S, Ogawa F, Yasuda M, Shimizu M: Primary signet-ring cell carcinoma of the lung: a report of 2 cases. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):771-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Signet-ring cell carcinoma is a distinct subtype of mucin-producing adenocarcinoma that originates in various organs, particularly the stomach.
  • The preoperative identification of signet-ring cells by cytologic examination is vital because signet-ring cell carcinoma of the lung has been reported to have a worse prognosis than ordinary adenocarcinoma.
  • Although the clusters were equivocal in the first case, the presence of more atypical cell clusters led to the diagnosis of adenocarcinoma.

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053537.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Suttie SA, Park KG, Smith TA: [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. Br J Cancer; 2007 Oct 8;97(7):902-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
  • Decreased tumour [(18)F]2-fluoro-2-deoxy-D-glucose ((18)FDG) incorporation is related to response however its significance at the cell level in gastro-oesophageal cancer and how it relates to cell death is unknown.
  • Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer. (18)FDG incorporation was determined after 48 and 72 h of treatment with each drug and related to drug-induced changes in glucose transport, hexokinase activity, cell cycle distribution and annexin V-PE binding (a measure of apoptosis).
  • Our results show that at the tumour cell level in gastric tumour cells, decreased (18)FDG incorporation and glucose transport, accompanies therapeutic growth inhibition. (18)FDG incorporation is particularly diminished in cells exhibiting apoptosis.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18 / pharmacokinetics. Stomach Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2006 Sep;47(9):1525-30 [16954562.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):425-39 [3005521.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):936-42 [3802100.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3119-23 [2823120.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] J Natl Cancer Inst. 1990 May 2;82(9):749-55 [1691303.001]
  • [Cites] Cancer Cells. 1990 Aug-Sep;2(8-9):275-80 [2223389.001]
  • [Cites] Biochem Pharmacol. 1990 Nov 15;40(10):2353-62 [2244936.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(3):189-92 [1628367.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] J Nucl Med. 1993 Mar;34(3):414-9 [8441032.001]
  • [Cites] Eur J Biochem. 1994 Feb 1;219(3):713-25 [8112322.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10):1811-7 [7562048.001]
  • [Cites] Oncology. 1996 Jan-Feb;53(1):19-26 [8570126.001]
  • [Cites] Br J Biomed Sci. 1999;56(4):285-92 [10795374.001]
  • [Cites] Br J Biomed Sci. 2000;57(2):170-8 [10912295.001]
  • [Cites] Cell Mol Life Sci. 2000 Aug;57(8-9):1229-35 [11028915.001]
  • [Cites] J Nucl Med. 2000 Oct;41(10):1753-9 [11038008.001]
  • [Cites] J Nucl Med. 2001 Jan;42(1):170-5 [11197971.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):657-63 [11259608.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3058-65 [11408502.001]
  • [Cites] Nucl Med Commun. 2002 Jun;23(6):545-50 [12029209.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3515-20 [12067998.001]
  • [Cites] Biochemistry. 2002 Oct 22;41(42):12639-51 [12379106.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9 [12397465.001]
  • [Cites] Mol Imaging Biol. 2003 Sep-Oct;5(5):337-46 [14630513.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):56-68 [14734674.001]
  • [Cites] Nucl Med Biol. 2004 Jan;31(1):1-9 [14741565.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1500-7 [14977854.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):926-32 [15027127.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):955-65 [15492778.001]
  • [Cites] Anticancer Drugs. 2004 Sep;15(8):809-18 [15494644.001]
  • [Cites] J Nucl Med. 1978 Oct;19(10):1154-61 [214528.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Trends Neurosci. 2005 Mar;28(3):117-9 [15749163.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):675-82 [15809491.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):486-90 [15816463.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):660-7 [15660258.001]
  • [Cites] J Nucl Med. 2006 Apr;47(4):603-8 [16595493.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Biochem J. 1996 Feb 1;313 ( Pt 3):957-62 [8611181.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1164-7 [8640778.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):533-41 [8832712.001]
  • [Cites] Radiat Res. 1997 Jun;147(6):729-34 [9189172.001]
  • [Cites] J Surg Oncol. 1997 Jun;65(2):106-10 [9209521.001]
  • [Cites] Nucl Med Biol. 1994 Aug;21(6):835-45 [9234333.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1337-44 [9293783.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):339-43 [9387094.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):378-87 [9418885.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1403-6 [9782025.001]
  • [Cites] Nucl Med Biol. 1998 Oct;25(7):593-7 [9804039.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):309-17 [10023697.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):556-65 [10210213.001]
  • [Cites] J Nucl Med. 1999 Jul;40(7):1085-90 [10405124.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4709-14 [10493529.001]
  • [Cites] Cancer Res. 1955 Feb;15(2):105-8 [14352196.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):441-3 [17072613.001]
  • (PMID = 17848947.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360409
  •  go-up   go-down


80. Salehi Z, Mollasalehi H, Jelodar MH, Kazemi M, Zahmatkesh R: The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran. Oncol Res; 2010;18(7):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran.
  • Colonization of the human stomach with Helicobacter pylori induces chronic gastritis and is associated with the development of gastric and duodenal ulcers, gastric carcinoma, and gastric mucosa-associated lymphoid tissue lymphoma.
  • Infection with an H. pylori strain containing the cytotoxin-associated (cagA) gene (a marker for a pathogenicity island) may increase the risk of atrophic gastritis and gastric cancer.
  • The exact role of H. pylori in gastric carcinogenesis is still being investigated.
  • Hence, we assessed whether H. pylori infection is associated with the development of gastric adenocarcinoma in northern Iran.
  • Gastric biopsy specimens from 168 patients suffering from gastric adenocarcinoma, gastric ulcer, and non-ulcer dyspepsia were analyzed by means of the polymerase chain reaction. H. pylori was detected in the gastric mucosa of 34 (75.5%) gastric adenocarcinoma, 56 (88.8%) gastric ulcer, and 36 (60%) non-ulcer dyspepsia.
  • In patients with gastric adenocarcinoma, the cagA was less commonly found than those in noncancer patients (4/34 vs. 58/92, p < 0.05).
  • Our work suggests that although H. pylori infection is significantly associated with gastric adenocarcinoma in northern Iran, the cagA is not the dominant virulence in development of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / pathogenicity. Stomach Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Antigens, Bacterial / genetics. Bacterial Proteins / genetics. Female. Gastritis / microbiology. Gastritis / surgery. Humans. Iran. Male. Middle Aged. Prognosis. Stomach Ulcer / genetics. Stomach Ulcer / microbiology. Stomach Ulcer / surgery

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377133.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


81. Bigot P, Desbois E, Benoist N, Besnier L, Moui Y: [Isolated pain of the hand revealing a metastatic tumor of the hand. Report of a case]. Chir Main; 2007 Dec;26(6):300-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Acrométastase révélée par une douleur isolée de la main. A propos d'un cas.
  • We describe a patient with gastric cancer.
  • OBSERVATION: A 64-year-old man in remission of a gastric adenocarcinoma treated surgically one year previously was admitted to hospital for a pain of the right hand associated with an edema.
  • The anatomopathologic examination revealed an osseous metastasis of a gastric adenocarcinoma.
  • The patient died five months after the diagnosis of acrometastasis.
  • Evolution during acrometastasis of gastric cancer is the same one as in the other acrometastases.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Hand. Metacarpal Bones. Pain / etiology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Humans. Male. Middle Aged. Osteolysis / etiology. Prognosis. Radiotherapy Dosage. Stomach Neoplasms. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023234.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst; 2009 Jun 3;101(11):793-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
  • However, the clinical relevance of CIP2A to human cancers had not been demonstrated, but the mechanism of its regulation and its clinical role in cancer were completely unknown.
  • METHODS: Tissue microarrays consisting of 223 gastric adenocarcinoma specimens were evaluated for the presence of CIP2A using immunohistochemistry, and the association of CIP2A expression with survival was assessed using Kaplan-Meier analysis.
  • The effects of MYC and CIP2A on each other's expression and on cell proliferation were investigated in several gastric cancer cell lines using small interfering RNAs to CIP2A and MYC and immunoblotting.
  • RESULTS: Expression of CIP2A protein was associated with reduced overall survival for gastric cancer patients with tumors 5 cm or smaller, with a 10-year overall survival in the CIP2A-immunopositive group of 8.1% as compared with 37.6% in the CIP2A-negative group (difference = 29.5%, 95% confidence interval = 12.5% to 46.5%, P = .001).
  • In gastric cancer cell lines, CIP2A depletion led to decreased proliferation and anchorage-independent growth of the cells, as well as to reduced stability and expression of MYC protein.
  • Finally, CIP2A and MYC immunopositivities were associated in gastric cancer specimens (P = .021).
  • CONCLUSIONS: CIP2A immunopositivity is a predictor of survival for some subgroups of gastric cancer patients.
  • CIP2A and MYC appear to be regulated in a positive feedback loop, wherein they promote each other's expression and gastric cancer cell proliferation.
  • [MeSH-major] Adenocarcinoma / chemistry. Autoantigens / analysis. Biomarkers, Tumor / analysis. Feedback, Physiological. Membrane Proteins / analysis. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / chemistry


83. Ashktorab H, Dashwood RH, Dashwood MM, Zaidi SI, Hewitt SM, Green WR, Lee EL, Daremipouran M, Nouraie M, Malekzadeh R, Smoot DT: H. pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria. Helicobacter; 2008 Dec;13(6):506-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] H. pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria.
  • METHODS: Human gastric adenocarcinoma (AGS) cells were incubated with a cagA-positive H. pylori strain for 0, 3, 6, and 24 hours and either total protein or cytoplasmic, nuclear, and mitochondrial membrane fractions were collected.
  • Active AIF staining was markedly increased in gastric mucosa from infected persons, compared to uninfected controls.
  • This is consistent with AIF activation that was found in the gastric mucosa of humans infected with H. pylori.
  • Hence, the balance between apoptosis and proliferation in these cells may be altered in response to injury caused by H. pylori infection, leading to an increased risk of cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19166416.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK053713; United States / NIDDK NIH HHS / DK / DK53713; United States / NIDDK NIH HHS / DK / DK56664
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor
  •  go-up   go-down


84. Bae JM, Kim SW, Kim SW, Song SK: [Metachronous four primary malignancies in gastro-intestinal tract]. Korean J Gastroenterol; 2009 Jun;53(6):373-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, multiple primary malignancies are considered to increase due to improved survival rate of cancer patients, advanced diagnostic tools, and increased use of chemotherapy and radiotherapy.
  • Recently, we experienced a 70 year-old male who was diagnosed with metachronous four primary malignancies in rectum, ascending colon, stomach, and ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / diagnosis. Gastrointestinal Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Humans. Male. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556845.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


85. Quiding-Järbrink M, Sundström P, Lundgren A, Hansson M, Bäckström M, Johansson C, Enarsson K, Hermansson M, Johnsson E, Svennerholm AM: Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. Clin Immunol; 2009 Jun;131(3):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients.
  • Gastric adenocarcinoma is closely associated with Helicobacter pylori infection.
  • To investigate a possible link between local antibody production and gastric tumors, we studied gastric B cell infiltration and local IgA production in patients with H. pylori induced gastric adenocarcinomas.
  • These studies showed that total and H. pylori-specific IgA antibody levels were substantially lower in gastric tissue from the cancer patients compared to those from asymptomatic H. pylori carriers.
  • However, serum IgA levels were similar in the cancer patients and asymptomatic carriers.
  • We conclude that patients suffering from gastric adenocarcinoma have a dramatically decreased local IgA production in the stomach compared to asymptomatic H. pylori infected individuals.
  • [MeSH-major] Adenocarcinoma / immunology. Gastric Mucosa / immunology. Helicobacter Infections / immunology. Immunoglobulin A / immunology. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249247.001).
  • [ISSN] 1521-7035
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Chemokines; 0 / Immunoglobulin A; EC 3.5.1.5 / Urease
  •  go-up   go-down


86. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA: Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol; 2005 May 1;23(13):3094-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years.
  • PURPOSE: To determine the clinicopathologic behavior of gastric adenocarcinoma in Hispanics by comparing Hispanic and non-Hispanic patients treated at a single cancer center.
  • PATIENTS AND METHODS: Medical records of patients with invasive gastric cancer treated from 1985 to 1999 were reviewed.
  • Hispanics were significantly younger at diagnosis than non-Hispanic whites (53.1 +/- 14.4 years v 59.4 +/- 12.7 years, respectively; P < .005) or African Americans (57.6 +/- 15.3 years, P < .005).
  • Hispanics were less likely to have proximal gastric cancers compared with whites (38.9% v 59.5%, respectively; P < .005).
  • Among patients with metastases at diagnosis, Hispanics were less likely to have liver metastasis than whites (30% v 44%, respectively; P = .009) but more likely to have peritoneal metastasis than whites and African Americans (54% v 41% and 47%, respectively; P = .002).
  • CONCLUSION: Hispanic ethnicity does not impact survival in gastric adenocarcinoma.
  • However, histology, metastasis pattern, tumor localization, and other clinical parameters differ sufficiently to warrant further investigation into the epidemiology, pathogenesis, and molecular biology of gastric cancer in this population.
  • [MeSH-major] Adenocarcinoma / pathology. Hispanic Americans. Neoplasm Metastasis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860869.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Sakellariou S, Liakakos T, Ghiconti I, Hadjikokolis S, Nakopoulou L, Pavlakis K: Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res; 2008 Mar-Apr;28(2A):1079-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer.
  • BACKGROUND: P15 (a cyclin- D- kinase inhibitor) and SMAD4 (a signal transducer of the TGF-beta pathway) are two closely related proteins which may have an important role in gastric carcinogenesis.
  • MATERIALS AND METHODS: Sixty-three gastric carcinomas were studied.
  • CONCLUSION: P15 gene silencing might be an important event in the tumorigenesis of gastric adenocarcinomas of the intestinal type.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / metabolism. Smad4 Protein / metabolism. Stomach Neoplasms / metabolism


88. Baek KH, Jeon HM, Lee SS, Lim DJ, Oh KW, Lee WY, Rhee EJ, Han JH, Cha BY, Lee KW, Son HY, Kang SK, Kang MI: Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients. Bone; 2008 Jan;42(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term changes in bone and mineral metabolism following gastrectomy in gastric cancer patients.
  • This study investigated 46 patients undergoing gastrectomy for gastric adenocarcinoma and analyzed 36 patients (58.1+/-10.8 years, 24 men and 12 women) who had dual energy X-ray absorptiometry (DXA) performed before and 1 year after gastrectomy.
  • [MeSH-major] Bone Density / physiology. Bone and Bones / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942383.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Collagen Type I; 0 / Parathyroid Hormone; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide
  •  go-up   go-down


89. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT: Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut; 2007 Jun;56(6):782-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
  • OBJECTIVE: Osteopontin (OPN) has been found to be valuable in diagnosis and predicting the prognosis of a variety of malignancies.
  • The aims of the present study are to evaluate the usefulness of plasma OPN level for predicting gastric cancer development, invasion and survival.
  • PATIENTS AND METHODS: One hundred and thirty two gastric cancer patients and 93 healthy controls were enrolled.
  • Real-time quantitative reverse-transcription polymerase chain reaction and immunohistochemical staining were used to detect OPN expression in gastric cancer tissues.
  • Plasma OPN levels were compared with gastric cancer development, clinicopathological features and outcomes.
  • RESULTS: Expression of OPN mRNA was significantly higher in gastric cancer tissues compared with non-tumour tissues.
  • Most OPN immunoactivity was localised to cancer cells.
  • CONCLUSIONS: Elevated plasma OPN level is significantly associated with gastric cancer development, invasive phenotypes and survival.
  • Plasma OPN level may have potential usefulness as a diagnostic and prognostic factor for gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / blood. Osteopontin / blood. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(2):156-63 [10901364.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3337-43 [16740755.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:723-49 [11264474.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4245-51 [11709568.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] Cancer Lett. 2002 Oct 28;184(2):197-206 [12127692.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):506-12 [12209742.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):617-23 [12594817.001]
  • [Cites] J Cell Physiol. 2004 Jan;198(1):155-67 [14584055.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1749-58 [12919959.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11051-64 [14704150.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38921-35 [15247285.001]
  • [Cites] Science. 1987 Oct 23;238(4826):491-7 [2821619.001]
  • [Cites] Crit Rev Oncog. 1993;4(2):95-114 [8420573.001]
  • [Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]
  • [Cites] Science. 1996 Jan 26;271(5248):509-12 [8560266.001]
  • [Cites] Radiol Clin North Am. 1997 Mar;35(2):331-49 [9087207.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4237-46 [10435636.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17(2):132-8 [10449685.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19381-92 [15757900.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Mar;27(3):167-9 [15946568.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 May;27(5):292-5 [15996323.001]
  • [Cites] Nihon Ronen Igakkai Zasshi. 1999 Nov;36(11):799-802 [10655737.001]
  • [Cites] Science. 2000 Feb 4;287(5454):860-4 [10657301.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2734-42 [10733576.001]
  • [Cites] Oncology. 2005;68(2-3):285-92 [16015046.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):453-7 [16091764.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6459-65 [16166420.001]
  • [Cites] Lancet Oncol. 2005 Oct;6(10):757-64 [16198981.001]
  • [Cites] J Surg Res. 2005 Nov;129(1):94-100 [16054651.001]
  • [Cites] Cancer Biol Ther. 2005 Dec;4(12):1336-41 [16258259.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Cancer Treat Rev. 2000 Aug;26(4):243-55 [10913380.001]
  • (PMID = 17148500.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC1954839
  •  go-up   go-down


90. Jeong EG, Lee SH, Lee HW, Soung YH, Yoo NJ, Lee SH: Immunohistochemical and mutational analysis of FLASH in gastric carcinomas. APMIS; 2007 Aug;115(8):900-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and mutational analysis of FLASH in gastric carcinomas.
  • Although such functions are important in cancer pathogenesis, little is known about the alterations of FLASH gene and FLASH protein expression in human cancers.
  • In this study, we analyzed the expression of FLASH protein in 60 gastric adenocarcinomas by immunohistochemistry.
  • We furthermore analyzed mutation of FLASH in exon 8, where two polyadenine tracts ((A)8 and (A)9) are present, by single-strand conformation polymorphism (SSCP) assay in 184 gastric adenocarcinomas.
  • By immunohistochemistry, FLASH protein expression in cancer cells was detected positively in 42 gastric carcinoma tissues (70%), whereas its expression in epithelial cells of normal gastric mucosa was shown as no or very weak intensity.
  • Mutational analysis detected one FLASH mutation in the gastric carcinomas (0.5%).
  • The increased expression of FLASH in the malignant gastric epithelial cells compared to the normal mucosal epithelial cells suggests that FLASH expression may play a role in gastric tumorigenesis.
  • Also, the data suggest that somatic mutation of FLASH is a rare event in gastric carcinomas.
  • [MeSH-major] Apoptosis Regulatory Proteins / analysis. Calcium-Binding Proteins / analysis. Mutation. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696945.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CASP8AP2 protein, human; 0 / Calcium-Binding Proteins
  •  go-up   go-down


91. Aydin S, Ozercan IH, Dagli F, Aydin S, Dogru O, Celebi S, Akin O, Guzel SP: Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland. Biotech Histochem; 2005 May-Aug;80(3-4):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ghrelin immunohistochemistry of gastric adenocarcinoma and mucoepidermoid carcinoma of salivary gland.
  • Ghrelin (G-HH) synthesized in several tissues including salivary and stomach glands stimulates appetite in humans by modulating neuropeptide Y neurons in the hypothalamic arcuate nucleus.
  • Loss of appetite is one of the most important symptoms of stomach cancer.
  • We conducted a study using immunohistochemistry to determine whether salivary glands and stomach cancer tissues produce ghrelin.
  • We determined that negative ghrelin immunohistochemistry discriminates tumors from normal tissues and may therefore further our understanding of the clinically important problem of reduced food intake and anorexia in cancer patients.
  • Radioimmunoassay analyses confirmed that cancer cells do not produce a G-HH peptide, whereas normal cells yield this peptide.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Mucoepidermoid / metabolism. Peptide Hormones / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298902.001).
  • [ISSN] 1052-0295
  • [Journal-full-title] Biotechnic & histochemistry : official publication of the Biological Stain Commission
  • [ISO-abbreviation] Biotech Histochem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ghrelin; 0 / Peptide Hormones
  •  go-up   go-down


92. Catalano F, Trecca A, Rodella L, Lombardo F, Tomezzoli A, Battista S, Silano M, Gaj F, de Manzoni G: The modern treatment of early gastric cancer: our experience in an Italian cohort. Surg Endosc; 2009 Jul;23(7):1581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The modern treatment of early gastric cancer: our experience in an Italian cohort.
  • BACKGROUND: Endoscopic submucosal dissection (ESD) has been developed as treatment for early gastric cancer (EGC) by Japanese authors.
  • METHODS: Forty-five patients for a total of 48 gastric lesions were enrolled in the study.
  • We define as curative treatment lateral and vertical margins of the resected specimens free of cancer and repeat endoscopic finding of no recurrent disease.
  • [MeSH-major] Adenocarcinoma / surgery. Gastroscopy / methods. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cohort Studies. Coloring Agents. Dissection. Early Diagnosis. Equipment Design. Female. Gastric Mucosa / surgery. Gastroscopes. Humans. Indigo Carmine. Italy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. INDIGO .
  • Hazardous Substances Data Bank. Indigotindisulfonate sodium .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Jun;24(6):1505 [20035354.001]
  • [CommentIn] Surg Endosc. 2010 Jun;24(6):1507-9 [20044771.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2001 Jul;11(3):511-8 [11778752.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):877-83 [17140890.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):58-62 [8454147.001]
  • [Cites] Gastric Cancer. 2006;9(4):262-70 [17235627.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):596-601 [16564858.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):1001-6 [17058165.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):495-9 [11696619.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3174-8 [8242540.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Surgery. 1999 Feb;125(2):148-54 [10026747.001]
  • [Cites] Tumori. 2007 Jul-Aug;93(4):367-73 [17899867.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):788-801 [15326574.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):987-90 [17058162.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):221-6 [11293753.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):776-82 [16650537.001]
  • [Cites] Gastric Cancer. 2000 Dec;3(4):219-225 [11984739.001]
  • [Cites] BMJ. 1993 Sep 4;307(6904):591-6 [8401015.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):576-81 [11923778.001]
  • [Cites] Br J Surg. 1987 Jul;74(7):618-9 [3620874.001]
  • [Cites] Gastric Cancer. 2007;10(1):1-11 [17334711.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):602-6 [8616749.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):929-42 [17096062.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):819-22 [10570343.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1146-53 [17576611.001]
  • [Cites] Gastric Cancer. 2006;9(1):3-8 [16557429.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):567-79 [12665775.001]
  • [Cites] Endoscopy. 1995 Jan;27(1):27-31 [7601031.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):212-8 [16860071.001]
  • (PMID = 19263148.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; D3741U8K7L / Indigo Carmine
  •  go-up   go-down


93. Coburn NG, Swallow CJ, Kiss A, Law C: Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer; 2006 Nov 1;107(9):2143-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer.
  • BACKGROUND: Lymph node (LN) status is a major determinant of prognosis and treatment of gastric adenocarcinoma.
  • The 1997 American Joint Commission on Cancer/Union Internationale Contre le Cancer guidelines were revised, requiring examination of > or =15 LN for staging.
  • METHODS: We investigated compliance with these guidelines and the correlation with overall survival (OS) by analyzing 10,807 resected gastric cancers in the Surveillance, Epidemiology and End Results (SEER) database, 1988-2002.
  • Factors predictive of adequate LN assessment (ALNA) were higher stage, worse grade, age <74 years, later year of diagnosis, nonwhite race, more extensive surgery, female sex, and SEER region.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging / standards. SEER Program. Stomach Neoplasms / diagnosis. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17001662.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Mojtahedi A, Salehi R, Navabakbar F, Tamizifar H, Tavakkoli H, Duronio V: Evaluation of apoptosis induction using PARP cleavage on gastric adenocarcinoma and fibroblast cell lines by different strains of Helicobacter pylori. Pak J Biol Sci; 2007 Nov 15;10(22):4097-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of apoptosis induction using PARP cleavage on gastric adenocarcinoma and fibroblast cell lines by different strains of Helicobacter pylori.
  • Helicobacter pylori is one of the most common pathogens affecting humans and is the major environmental factor in the development of gastric cancer increasing from 4 to 6 folds the risk of its development.
  • Variations in cancer risk among H. pylori infected individuals may correlate to difference in H. pylori strains, variable host characteristics and specific interactions between host and microbial determinants.
  • [MeSH-major] Adenocarcinoma / microbiology. Apoptosis. Fibroblasts / microbiology. Helicobacter pylori / metabolism. Poly(ADP-ribose) Polymerases / metabolism. Stomach Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19090286.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori; 0 / cagA protein, Helicobacter pylori; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  •  go-up   go-down


95. López-Tarruella Cobo S, Moreno Antón F, Sastre J, López García-Asenjo JA, Torres A, Díaz-Rubio E: Cuirasse skin metastases secondary to gastric adenocarcinoma. Clin Transl Oncol; 2005 Jun;7(5):213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cuirasse skin metastases secondary to gastric adenocarcinoma.
  • Skin metastases from gastric adenocarcinomas are particularly rare, and represent 6% of the total in males and 1% in females.
  • We report, here, the case of a patient diagnosed with gastric adenocarcinoma with extensive subcutaneous infiltration of the abdominal wall, resulting in an abdominal cuirass.
  • [MeSH-major] Adenocarcinoma / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2001;19(5):554-68 [11458821.001]
  • [Cites] Arch Anat Cytol Pathol. 1996;44(1):60-4 [8762894.001]
  • [Cites] Med Clin North Am. 1980 Sep;64(5):885-900 [7432046.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):228-36 [8335743.001]
  • [Cites] Eur J Cancer Care (Engl). 2002 Jun;11(2):143-4 [12099951.001]
  • [Cites] An Med Interna. 2003 May;20(5):251-3 [12831300.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Jun;20(2):297-9 [11484991.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] Radiat Med. 1989 Mar-Apr;7(2):95-104 [2477873.001]
  • [Cites] Cancer. 1965 Jul;18:907-15 [14308240.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] Eur J Dermatol. 2002 Jan-Feb;12(1):85-7 [11809606.001]
  • [Cites] Arch Dermatol. 1972 Jun;105(6):862-8 [5030236.001]
  • (PMID = 15960933.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Yamamoto J, Ohshima K, Kohno S, Ichimiya H, Nakagaki M, Yao T, Iwasaki H, Ikeda S: Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case. Surg Today; 2005;35(6):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case.
  • Extremely well differentiated primary gastric adenocarcinoma, which accounts for less than 0.2% of all gastric cancers, is associated with a better prognosis than other types of differentiated adenocarcinoma.
  • Among 2070 gastric carcinomas, diagnosed between 1983 and 2002 at Fukuoka University Hospital and Hamanomachi Hospital, there were three cases of primary extremely well differentiated adenocarcinoma.
  • We report the clinicopathological details of one case of primary gastric extremely well differentiated adenocarcinoma.
  • A 57-year-old man was reffered to our hospital for investigation and treatment of a gastric tumor.
  • Macroscopically, the surgical specimen contained a submucosal tumor, and histological examination revealed extremely well differentiated adenocarcinoma.
  • Although this type of carcinoma is very rare, it should be considered in the differential diagnosis of esophageal and gastric mucosal lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Achalasia / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Cardia / pathology. Cell Differentiation. Cholecystectomy. Endoscopy, Digestive System. Esophagus / radiography. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • Genetic Alliance. consumer health - Achalasia.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912298.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Fu S, Lu JJ, Zhang Q, Yang Z, Peng L, Xiong F: Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1488-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma.
  • PURPOSE: To evaluate the efficacy of intraoperative radiotherapy (IORT) followed by concurrent chemotherapy and external beam RT (EBRT) in the treatment of locally advanced gastric adenocarcinoma.
  • METHODS AND MATERIALS: A total of 97 consecutive and nonselected patients with newly diagnosed Stage T3, T4, or N+ adenocarcinoma of the stomach underwent gastrectomy with D2 lymph node dissection between March 2003 and October 2005.
  • CONCLUSIONS: Radical gastrectomy with D2 lymph node dissection and IORT followed by adjuvant chemoradiotherapy appeared to be feasible and well-tolerated in the treatment of locally advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Radiotherapy / methods. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538489.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Lee JH, Ryu KW, Lee JS, Lee JR, Kim CG, Choi IJ, Park SR, Kook MC, Kim YW, Bae JM: Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly. J Surg Oncol; 2007 May 1;95(6):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly.
  • BACKGROUND AND OBJECTIVES: There is a prevailing belief that young patients with gastric adenocarcinomas have a more aggressive disease.
  • METHODS: We reviewed the prospectively collected database of 753 gastric adenocarcinomas patients who had undergone curative gastrectomy.
  • CONCLUSIONS: The present study showed that intra-operative under-staging was more common in young patients with gastric cancer, especially with stage I disease.
  • This finding raises the concern for inaccurate diagnosis and surgical under treatment in younger patients with stage I gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17195172.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Coban S, Ozkan H, Köklü S, Yüksel O, Koçkar MC, Akar T, Ormeci N: The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can J Gastroenterol; 2006 Sep;20(9):593-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers.
  • BACKGROUND: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a novel tumour marker that has been described in various kinds of cancer.
  • PATIENTS AND METHODS: Sera collected from patients with GI cancers (14 esophagus, 32 gastric and 36 colon) and from healthy volunteers (30 individuals) were analyzed for RCAS1 and compared with carcinoembryonic antigen (CEA) and cancer antigen 19-9.
  • Among GI tract cancers, RCAS1 had lowest and highest sensitivity for esophagus and colon cancer diagnosis, respectively.
  • In comparison with cancer antigen 19-9, serum RCAS1 was more sensitive but less specific for all GI cancer groups.
  • [MeSH-minor] Adenocarcinoma / immunology. Adult. Aged. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Squamous Cell / immunology. Case-Control Studies. Colonic Neoplasms / immunology. Esophageal Neoplasms / immunology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity. Stomach Neoplasms / immunology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2003 Oct;56(10):764-8 [14514780.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1669-74 [14571813.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):679-85 [12861064.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):310-5 [12845666.001]
  • [Cites] Pancreas. 2003 Jan;26(1):49-55 [12499917.001]
  • [Cites] Oncology. 2003;64(1):83-9 [12457035.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):418-23 [11992411.001]
  • [Cites] Cancer Lett. 2002 Mar 8;177(1):101-5 [11809537.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):446-51 [11466701.001]
  • [Cites] Cancer Lett. 2001 Jul 26;168(2):197-202 [11403925.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):91-6 [11391627.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):488-93 [11102892.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1891-4 [14534714.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Dec;25(4):805-20 [8960894.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1501-9 [8608535.001]
  • [Cites] Dig Liver Dis. 2004 Sep;36(9):622-7 [15460847.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):259-67 [15254686.001]
  • [Cites] Int J Hematol. 2004 May;79(4):340-4 [15218962.001]
  • [Cites] Cancer Sci. 2004 Mar;95(3):260-5 [15016327.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):4967-71 [14981953.001]
  • [Cites] J Hepatol. 2003 Oct;39(4):559-63 [12971966.001]
  • (PMID = 17001401.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / EBAG9 protein, human
  • [Other-IDs] NLM/ PMC2659945
  •  go-up   go-down


100. Enarsson K, Johnsson E, Lindholm C, Lundgren A, Pan-Hammarström Q, Strömberg E, Bergin P, Baunge EL, Svennerholm AM, Quiding-Järbrink M: Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin Immunol; 2006 Jan;118(1):24-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa.
  • Worldwide, gastric adenocarcinoma (GC) is the second most common cause of death from malignant disease.
  • [MeSH-major] Adenocarcinoma / immunology. Cell Movement / immunology. Gastric Mucosa / immunology. Receptors, Lymphocyte Homing / immunology. Stomach Neoplasms / immunology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157508.001).
  • [ISSN] 1521-6616
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / CXCR3 protein, human; 0 / Immunoglobulins; 0 / L-selectin counter-receptors; 0 / LPL binding proteins, human; 0 / MADCAM1 protein, human; 0 / Membrane Proteins; 0 / Mucoproteins; 0 / Receptors, CXCR3; 0 / Receptors, Cell Surface; 0 / Receptors, Chemokine; 0 / Receptors, Lymphocyte Homing
  •  go-up   go-down






Advertisement